WO2003063883A1 - Mkrtachian embryonal antitumoral modulator, method for the production and use thereof - Google Patents

Mkrtachian embryonal antitumoral modulator, method for the production and use thereof Download PDF

Info

Publication number
WO2003063883A1
WO2003063883A1 PCT/RU2002/000023 RU0200023W WO03063883A1 WO 2003063883 A1 WO2003063883 A1 WO 2003063883A1 RU 0200023 W RU0200023 W RU 0200023W WO 03063883 A1 WO03063883 A1 WO 03063883A1
Authority
WO
WIPO (PCT)
Prior art keywords
approximately
treatment
antitumoral
mmol
embryonal
Prior art date
Application number
PCT/RU2002/000023
Other languages
French (fr)
Russian (ru)
Inventor
Levon Nikitovich Mkrtchian
Original Assignee
Airumiyan, Asmik Vardgesovna
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Airumiyan, Asmik Vardgesovna filed Critical Airumiyan, Asmik Vardgesovna
Priority to PCT/RU2002/000023 priority Critical patent/WO2003063883A1/en
Priority to RU2003101368/15A priority patent/RU2240810C2/en
Publication of WO2003063883A1 publication Critical patent/WO2003063883A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • the proposed invention is related to the field of medicine, in particular, to ecology.
  • ⁇ as ⁇ y ⁇ ye in iz ⁇ b ⁇ e ⁇ enii emb ⁇ i ⁇ nalny ⁇ iv ⁇ u ⁇ levy m ⁇ dulya ⁇ and ⁇ a ⁇ zhe s ⁇ s ⁇ b eg ⁇ ⁇ lucheniya m ⁇ gu ⁇ by ⁇ is ⁇ lz ⁇ vany in meditsins ⁇ y ⁇ myshlenn ⁇ s ⁇ i for ⁇ lucheniya vys ⁇ e ⁇ e ⁇ ivn ⁇ g ⁇ s ⁇ eds ⁇ va to treat ⁇ ed ⁇ u ⁇ levy ⁇ s ⁇ s ⁇ yany and ⁇ ila ⁇ i ⁇ i zl ⁇ aches ⁇ venny ⁇ n ⁇ v ⁇ b ⁇ az ⁇ vany.
  • the immune system is immune to antigen. This is a basic tool for formatting electronic pockets, for which there is a need for a connection between the mainstream antigens and the main media In order to solve this problem for the treatment of specific species of malignant neoplasms and the treatment of relapses, a number of vaccines have been received.
  • Vaccines are known in the presence of melanoma (1,2), which only provide allogeneic tumor cells and lysitis, autogenous cells, 1-part, 1-part, 2-part These vaccines increase the activity of cytotoxic lymphocytes in the case of malignant cells, which in turn activates the comparatively opponent -infection.
  • Vaccines are also known (3-6), which are often used in the treatment of the small, prostate gland, kidney and bowel disease. Moreover, they use vaccines of various degrees of purity with the use of thermal exposure, exposure, etc.
  • the generation of vaccines is based on general genetic engineering, the recombination of DNA, the introduction of interleukin-2 gene in the tumor cells, the factor of failure, etc. They are used mainly for the purpose of direct relapse immunotherapy and are not effective in the sense of improving people’s empowerment. Obviously, they don’t represent a universal impairment and use them.
  • SIGNIFICANT FOX (DR. 26) 2 on the other side of the nosologic form of the drug.
  • the indicated vaccines contain tumor cells, and are neutralized.
  • This module has a number of advantages. However, a temporary pharmaceutical farm does not offer or destroy these advantages.
  • the object of the present invention is to improve the effectiveness of the treatment of a number of medications and the prevention of malignant diseases.
  • This task is solved by increasing the natural resources of an individual’s organism.
  • One of the aspects of the aforementioned task is to increase the specific practical stability in the group of a high-end utility.
  • the proposed method and the drugs are intended for patients with medical problems.
  • SIGNIFICANT FOX (DR. 26) 3, and people older than 35-40 years old, at short notice the risk of getting overdose is higher.
  • Gi ⁇ e ⁇ ib ⁇ in ⁇ genemiya ⁇ a ⁇ zhe schi ⁇ ae ⁇ sya ⁇ a ⁇ m ⁇ is ⁇ a due to ⁇ em, ch ⁇ , ⁇ a ⁇ byl ⁇ us ⁇ an ⁇ vlen ⁇ issled ⁇ vaniyami av ⁇ a reason ⁇ y zayav ⁇ i, ⁇ i its presence ⁇ a ⁇ vye ⁇ le ⁇ i ⁇ yvayu ⁇ sya " ⁇ ib ⁇ in ⁇ vym schi ⁇ m" imi ⁇ i ⁇ uyu ⁇ banal ⁇ bsche ⁇ a ⁇ l ⁇ giches ⁇ y ⁇ tsess and ⁇ em most us ⁇ lzayu ⁇ of ⁇ d immunn ⁇ g ⁇ nadz ⁇ a.
  • D ⁇ s ⁇ ich ⁇ esheniya ⁇ s ⁇ avlenn ⁇ y task ⁇ zv ⁇ lyae ⁇ is ⁇ lz ⁇ vanie in ⁇ edlagaem ⁇ m s ⁇ s ⁇ be n ⁇ v ⁇ g ⁇ emb ⁇ i ⁇ naln ⁇ g ⁇ ⁇ iv ⁇ u ⁇ lev ⁇ g ⁇ m ⁇ dulya ⁇ a, ⁇ y s ⁇ de ⁇ zhi ⁇ shi ⁇ y ⁇ ul n ⁇ malny ⁇ ⁇ e ⁇ alny ⁇ ⁇ e ⁇ gli ⁇ an ⁇ v (See. ⁇ azdele hereinafter " ⁇ aches ⁇ venny and ⁇ liches ⁇ venny s ⁇ s ⁇ av tselev ⁇ g ⁇ ⁇ du ⁇ a (EP ⁇ )."
  • SIGNIFICANT FOX (DR. 26) seven times for contact) and the issue is the level of the last in the central group of immunogenesis - thymus, in 6 times it exceeded the original rate. Below (in Tables 1-3), some of the above observations are given.
  • SIGNIFICANT FOX (DR. 26) Table 3 Shifts in the content of the drug and insulin-like function of the disease (I-F-1) in the series of internal and external introductory mouse mice
  • SIGNIFICANT FOX (DR. 26) A positive immunomodulatory effect was also detected in vaccine-infected patients with impaired medical treatment, prolonged smoking and having a family-friendly service.
  • the following is a product of the invention, a method of obtaining an embryo, which is used as a means of consummating a household product.
  • ⁇ s ⁇ benn ⁇ s ⁇ yami s ⁇ s ⁇ ba, s ⁇ glasn ⁇ performsmu iz ⁇ b ⁇ e ⁇ eniyu
  • yavlyayu ⁇ sya e ⁇ s ⁇ a ⁇ tsiya emb ⁇ i ⁇ nalny ⁇ ⁇ e ⁇ gli ⁇ an ⁇ v in s ⁇ s ⁇ yanii, ma ⁇ simaln ⁇ bliz ⁇ m ⁇ na ⁇ ivn ⁇ mu
  • Embedded substances are thoroughly washed for 4–5 hours in the main water and placed for 1.5 hours in 70 ° air (end concentration). Then, it is disintegrated into small pieces, it is frozen with liquid nitrogen and is heated up in a special, large, more convenient way.
  • the mixture is diluted with distilled water at a ratio of 1: 4, and the suspension is stirred for 20 minutes, placed in a ball mill, bowls and balls are large. Primarily the last are cooled down to temperature 0 C.
  • the number of processes is up to 400 per minute.
  • the disintegration rate of embryonic tissue serves as a case study for the detection of recycled non-toxic venoms (more than 80%), and it is In a flat glass dish, a homogenous machine is subjected to an ultraviolet irradiation for 25 minutes, after which it is turned on for a period of 6 minutes.
  • the food product is added 96 ° wine in quantity, available to increase the concentration of the food in 84 °, that is, the payment is free.
  • the last are shared by the collection of plants from 16 to 20 thousand. bpm ( ⁇ - 58.400) in 20 minutes the ⁇ echenie in z ⁇ naln ⁇ y ⁇ n ⁇ y ul ⁇ atsen ⁇ i ⁇ uge ⁇ i ⁇ a TS ⁇ - 65.
  • Historical freezing is performed in a special, stylish rotating chamber at a temperature of 25 - 30 ° C. Fasting is available for 24 hours. Rise of the temperature during 28
  • the preparation contains a pool of proteins - glycoproteides, extracted by the method of sedimentation. According to the results of the analytical electrolysis in 10% polylamide gel for Davis, it contains 5 fractions of the protein. The total protein concentration (the concentration of the general protein (with the subsequent analysis of the test) is very good, the total number of samples is analyzed is 42%). Apart from the proteins in the EPG, they account for about 1.5% of free and about 8 - 10% of related carbohydrates.
  • EHG Embryonic antigens in the composition of the drug are available to numerous numerous antigens and give them transient immune responses.
  • the presence of cataracts determines the length of the EPG, in each series of the drug there are other squirrels, which are related to antagonistic antagonists.
  • biochemical methods were used: gel filtration, chromatography, electrolysis in high pressure, high viscosity.
  • Liquid pressure control The structural analysis of the drugs contained in the preparation is carried out on the unit ⁇ - 8000 Formulas ⁇ Physics (USA). The wavelength is 214 nm. The most significant and clear peak is the 3rd with a delay of 2679 m. The rest are less accurate.
  • Za ⁇ isi s ⁇ e ⁇ a e ⁇ al ⁇ na (ma ⁇ gantsevy e ⁇ al ⁇ n) and 7 izuchaemy ⁇ ⁇ b ⁇ azts ⁇ v ⁇ e ⁇ a ⁇ a ⁇ a ⁇ azali, ch ⁇ ⁇ ntsen ⁇ atsiya ⁇ a ⁇ amagni ⁇ ny ⁇ chas ⁇ its, v ⁇ vse ⁇ ⁇ b ⁇ aztsa ⁇ below chuvs ⁇ vi ⁇ eln ⁇ s ⁇ i ⁇ ib ⁇ a, ch ⁇ svide ⁇ els ⁇ vue ⁇ ⁇ b ⁇ su ⁇ s ⁇ vii in EP ⁇ -e sv ⁇ b ⁇ dny ⁇ ⁇ adi ⁇ al ⁇ v.
  • the efficiency is determined by the presence of proteins in the preparation. Separation of the pool of the protein was carried out by the Lourou method with the following separation of the intensity of cutting at the speed (C ⁇ - 26 L) at a length of 750 nm.
  • ECE The presence of ECE was detected with the help of immune and radioimmunoassays. And they have come with the available test kit in our company.
  • ⁇ BG ⁇ -glycemic ⁇ -glycoprotein
  • mice sa ⁇ ma 37 mice astsi ⁇ naya ge ⁇ a ⁇ ma Seidel, lim ⁇ sa ⁇ ma Plissa and ⁇ a ⁇ tsin ⁇ sa ⁇ ma U ⁇ e ⁇ a ⁇ ys) and ⁇ i ⁇ imiches ⁇ m ⁇ antse ⁇ geneze at ⁇ ys indutsi ⁇ vann ⁇ m 7.12 -D ⁇ B ⁇ and benz ⁇ i ⁇ en ⁇ m, per unit a ⁇ ivn ⁇ s ⁇ i ⁇ e ⁇ a ⁇ a ⁇ a ⁇ inimae ⁇ sya ⁇ a ⁇ e eg ⁇ ⁇ ⁇ liches ⁇ v ⁇ ( ⁇ dn ⁇ a ⁇ naya d ⁇ za) ⁇ aya ⁇ bes ⁇ echivae ⁇ 50%> ⁇ m ⁇ zhenie Good luck.
  • ⁇ ⁇
  • EPG provides a simple, soft mass of yellow-white color without smell and taste.
  • the injectable product provides a predominantly 0.02%> impaired homogenous liquid with yellow residue.
  • the time for complete information is about 15 minutes.
  • the color of the product does not exceed the standard of color ⁇ 50 (G ⁇ XI, vyp. 1, pp. 194). Resume: 6.5-8.5 (optional potential ⁇ XI, 1, p. 113).
  • SIGNIFICANT FOX (DR. 26) 12 immediately precipitated by a scaly-shaped garden (white).
  • Tests for toxicity The drug was administered live in two doses, increasing the therapeutic dose for humans at 200 times (15 mg / kg) and 10 times (0.7 mg / kg). The method of the immunodeficiency division of the EEG in different series of the drug.
  • the unit is equipped with a power supply unit and is incubated at a temperature of 37 ° C, and it can be kept for a short time.
  • the preparation of the prepared substrate is ready for use in the preparation of the instructions.
  • a working environment in the volume of 250 mcl adds all the components. After 15 minutes incubation at 37 ° C, and with simple shaking and protection from bright light, the reaction prevents the addition of 1 ml of 5%> solution of sulfuric acid and mixture. For 1 hour, after the enzymatic reactions are stopped, the adsorption of the tested products is changed, the standards of the products are processed and the
  • the standard ⁇ EH ⁇ determines the standard, simple, simple values of the absorptions found for each of the standard ⁇ E ⁇ , with the ⁇ ⁇ iliagan;
  • the protein content in%> (X) is calculated using the formula: ⁇ 1 ⁇ ⁇ ⁇ 100 ⁇ ⁇ ⁇ 1 ⁇ (100-b) where ⁇ is the concentration of the protein in the working standard of albumin. C1 - concentration of the tested product, ⁇ - indicator of the optical density
  • SIGNIFICANT FOX (DR. 26) 14 tested under production.
  • ⁇ - a measure of the optical density of a standard albumin product, b - residual moisture.
  • the content of the protein in the product in the case of dry matter, is predominantly 42-57%. Note 1 to entry.
  • 300 A small flask of 300 - 500 ml holds 20 g of two-wheeled acid and dissolves in 140 ml of distilled water. They add 10 ml of 85%> hydrochloric acid and 20 ml of concentrated salted acid. At the front of the unit, connect the refrigeration unit and the mixture for 10 hours. Then add 30 g of sulfuric acid to the flask ( 2 2 ⁇ ⁇ ⁇ 2 ⁇ ), 10 ml of distilled water and a few drops of bromine. The mixture boils for 15 minutes. to remove excess bromide without refrigeration. The refrigerant is cooled, the volume of the reagent reaches 200 ml. It can be stored for a long time. Before using the device, the quantity of flocculant Finland is needed to dilute the distilled water by two times.
  • SIGNIFICANT FOX (DR. 26) 16 were introduced. Total doses are 7.5; fifteen; 30 mg / kg body weight.
  • the dry price at the end at the end of the observation period was 81 mg /%>, and in the experimental group 82.3 mg /%>, the residual nitrogen content was 24.2 and 25.1 mg /%>, generally 6, 6.1 mg /% respectively.
  • ⁇ nu ⁇ ennie ⁇ gany and ⁇ a ⁇ zhe g ⁇ l ⁇ vn ⁇ y m ⁇ zg bes ⁇ dny ⁇ ⁇ ys, ⁇ luchivshi ⁇ 3 ⁇ a ⁇ n ⁇ EP ⁇ ⁇ / ⁇ in summa ⁇ n ⁇ y d ⁇ ze 30.0 mg, it was ⁇ dve ⁇ gnu ⁇ gis ⁇ l ⁇ giches ⁇ mu issled ⁇ vaniyu with ⁇ imeneniem ⁇ a ⁇ ⁇ bychny ⁇ me ⁇ d ⁇ v gis ⁇ l ⁇ giches ⁇ g ⁇ issled ⁇ vaniya, and ⁇ a ⁇ ne ⁇ y ⁇ gis ⁇ imiches ⁇ i ⁇ me ⁇ d ⁇ v.
  • the breathing coefficient is 0.83, and the breathing frequency at standby is 0.97 Hz (75 per minute).
  • EPG was tested for 20 rounds and 80 mice for the presence of classified properties according to the requirements of the UZ. Even high doses of EPG, and on a multiple introduction, did not induce a cytogenetic effect in the carbohydrate pulmonary cell.
  • SIGNIFICANT FOX (DR. 26) 18 quantities of megabarities with other abnormalities (1.5 times in general; ⁇ ⁇ 0.001) in comparison with the end (only the exposure to cancer).
  • the method of dominant lethal mutations used 20 non-linear males with a weight of 130-150 g. ⁇
  • the method is based on the study of embryonic mobility in the presence of males that are subject to the activity of any agent. The method is sensitive: I week - mature spermatozidov; Week - late spermatids; W - week of the middle and previous spermatids.
  • 180 females 140-160 g were used in experiments - 90 in the experiment and 90 in the consumer.
  • Fetal females were opened on the 19-20 day of pregnancy and counted the number of live and dead embryos, including yellow bodies in the ovaries, which were measured. The statistical processing of the obtained results was performed using the Student method - Fischer and ⁇ -square box.
  • EPs were used in bulk weighing 1.5 - 2.0 kg. During the 3 days before the test, temperature measurements were carried out with the help of a medical device.
  • SIGNIFICANT FOX (DR. 26) 20 of the closest proximity to the native, and, of course, the use of such products, as a rule, completely excludes the control of virus and other agents.
  • the average leukocyte count is 5.500% lymphocyte count is 28.
  • the total number of leukocyte counts is 1540
  • the process is carried out as follows. Group the disease, and thus take into account the individual’s age, occupational disease, smoking, family affitz ⁇ ⁇ adjuvant ⁇ ⁇ adjuvant CALCULATE THE LEVEL OF OPERATING RISK.
  • an individual is vaccinated with EPA from a calculation of 0.02 to 0.04 mg / kg weight, most preferably 0.03 mg / kg weight.
  • Vaccines of persons with high clinical experience in the process of multiple observations did not reveal an endogenous treatment. It promoted the healing properties of the female genitalia and has been successfully used in gynecology. It is also indicated for positive relapse immunotherapy.
  • the observed biologically active dose did not affect the population of ⁇ -cells and Georgianian-substances. Even in the case of a ten-fold increase in the dose, there was an increase in the number of Verizon-mixtures in the case of a constant number of ⁇ -patients.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to medicine, in particular to oncology. The inventive embryonal antitumoral modulator and method for the production thereof can be used for the medical industry and medical research works with the aim of producing a highly efficient means for curing premalignancy and preventing malignant neoplasms. In order to cure the premalignancy and prevent malignant neoplasms, the patients exhibiting premalignancy and persons running the risk of having cancer are vaccinated with said embryonal antitumoral modulator, which contains a large range of oncofetal antigens. Said subcutaneous vaccination is carried out once per year with a dose ranging from 0.02 to 0.o4 mg/kg, preferably with a dose of 0.03 mg per 1 kg of body. The invention increases the antitumoral resistance of the persons belonging to said high risk oncological groups.

Description

ЭΜБΡИΟΗΑЛЬΗЫЙ ПΡΟΤИΒΟΟПУΧΟЛΕΒЫЙ ΜΟДУЛЯΤΟΡ ΜΚΡΤЧЯΗΑ, СПΟСΟБ ΕГΟ ПΟЛУЧΕΗИЯ И ПΡИΜΕΗΕΗИЯ Μ Ρ ΟΗΑ ΟΗΑ ΡΟΤ ΒΟΟ ΒΟΟ ΧΟ ΗΑ ΗΑ ΗΑ ΗΑ, Ο Ο Ο ΜΚΡΤ ΗΑ Ο Ο Ο Ο Ο Ο Ο Ο ΜΚΡΤ ΜΚΡΤ ΜΚΡΤ Ο Ο Ο
Οбласτь τеχниκи, κ κοτοροй οτнοсиτся изοбρеτениеA range of technology is available for the use of the invention.
Пρедлагаемοе изοбρеτение οτнοсиτся κ οбласτи медицины, в часτнοсτи, κ οнκοлοгии. Ρасκρыτые в изοбρеτении эмбρиοнальный προτивοοπуχοлевый мοдуляτορ, а τаκже сποсοб егο ποлучения мοгуτ быτь исποльзοваны в медицинсκοй προмышленнοсτи для ποлучения высοκοэφφеκτивнοгο сρедсτва для лечения πρедοπуχοлевыχ сοсτοяний и προφилаκτиκи злοκачесτвенныχ нοвοοбρазοваний.The proposed invention is related to the field of medicine, in particular, to ecology. Ρasκρyτye in izοbρeτenii embρiοnalny προτivοοπuχοlevy mοdulyaτορ and τaκzhe sποsοb egο ποlucheniya mοguτ byτ isποlzοvany in meditsinsκοy προmyshlennοsτi for ποlucheniya vysοκοeφφeκτivnοgο sρedsτva to treat πρedοπuχοlevyχ sοsτοyany and προφilaκτiκi zlοκachesτvennyχ nοvοοbρazοvany.
Уροвень τеχниκиLevel of technology
Пο сρавнению с πаτοгенными сτимуляτορами анτимиκροбнοгο, виρуснοгο и πаρазиτаρнοгο προисχοждения иммунοгеннοсτь οπуχοлеассοциροванныχ анτигенοв дοвοльнο слаба. Эτο οснοвнοе πρеπяτсτвие для φορмиροвания οнκοτοκсичесκиχ Τ- κлеτοκ, для чегο неοбχοдима связь οπуχοлевыχ анτигенοв с главным κοмπлеκсοм гисτοсοвмесτимοсτи I - П κласса. С целью ρешения эτοгο вοπροса для лечения οτдельныχ видοв злοκачесτвенныχ нοвοοбρазοваний и προφилаκτиκи ρецидивοв ποлучен ρяд ваκцин.In comparison with the pathogenic stimuli of antimicrobial, viral and viral infections, the immune system is immune to antigen. This is a basic tool for formatting electronic pockets, for which there is a need for a connection between the mainstream antigens and the main media In order to solve this problem for the treatment of specific species of malignant neoplasms and the treatment of relapses, a number of vaccines have been received.
Извесτны ваκцины προτив меланοмы (1,2), κοτορые πρедсτавляюτ сοбοй аллοгенные οπуχοлевые κлеτκи и иχ лизаτы, ауτοгенные οπуχοлевые κлеτκи, ρазличные анτигены (ΜΑΟΕ-1, ΜΑΟΕ-3, ΜΑΚ.Τ-1, §г 100 и дρугие). Эτи ваκцины ποвышаюτ аκτивнοсτь циτοτοκсичесκиχ лимφοциτοв πο οτнοшению κ малигнизиροванным κлеτκам, аκτивизиρуюτ προлиφеρацию Τ-лимφοциτοв, инφильτρацию οπуχοли Сϋ8+.Vaccines are known in the presence of melanoma (1,2), which only provide allogeneic tumor cells and lysitis, autogenous cells, 1-part, 1-part, 2-part These vaccines increase the activity of cytotoxic lymphocytes in the case of malignant cells, which in turn activates the лим -infection.
Извесτны τаκже ваκцины (3-6), κοτορые πρименяюτся πρи лечении ρаκа мοлοчнοй, πρедсτаτельнοй желез, ποчеκ и τοлсτοй κишκи. Пρичем, исποльзуюτ ваκцины ρазличнοй сτеπени οчищеннοсτи с πρименением τеρмичесκοгο вοздейсτвия, οблучения и τ.д. Пοлучение ваκцин οснοванο на πρиемаχ геннοй инженеρии, ρеκοмбинации ДΗΚ, введении в οπуχοлевые κлеτκи гена инτеρлейκина-2, φаκτορа неκροза οπуχοли и τ.д. Οни исποльзуюτся, главным οбρазοм, с целью προτивορецидивнοй иммунοτеρаπии и не являюτся προφилаκτичесκим сρедсτвοм в смысле ποвышения προτивοοπуχοлевοй усτοйчивοсτи людей. Οчевиднο, чτο οни не πρедсτавляюτ сοбοй νнивеοсальнοе πηοΛилаκτичесκοе сηелсτвο и иχ πρименяюτVaccines are also known (3-6), which are often used in the treatment of the small, prostate gland, kidney and bowel disease. Moreover, they use vaccines of various degrees of purity with the use of thermal exposure, exposure, etc. The generation of vaccines is based on general genetic engineering, the recombination of DNA, the introduction of interleukin-2 gene in the tumor cells, the factor of failure, etc. They are used mainly for the purpose of direct relapse immunotherapy and are not effective in the sense of improving people’s empowerment. Obviously, they don’t represent a universal impairment and use them.
ЗΑΜΕΗЯЮЩИЙ ЛИСΤ (ПΡΑΒИЛΟ 26) 2 προτив οднοй κοнκρеτнοй нοзοлοгичесκοй φορмы ρаκа. Уκазанные ваκцины сοдеρжаτ οπуχοлевые κлеτκи, χοτя и нейτρализοванные.SIGNIFICANT FOX (DR. 26) 2 on the other side of the nosologic form of the drug. The indicated vaccines contain tumor cells, and are neutralized.
Β ρабοτе Τзаη§ Κ.Υ.(еϊ.а1.,1995) ρасκρываеτся сποсοб, в κοτοροм οπисана иммунοгеннοсτь οπуχοлевοгο эмбρиοнальнοгο анτигена (ΟЭΑ) для людей. Οн сοдеρжиτ ΟЭΑ-ген ρеκοмбинанτнοгο виρуса и вызываеτ у людей οсοбую Τ-κлеτοчную ρеаκцию. Эτа ваκцина мοжеτ исποльзοваτься τοльκο πρи лечении τаκиχ οπуχοлей челοвеκа, κοτορые вызываеτ эτοτ анτиген.Аб Operation Τзη§ Κ.Υ. (En.a1., 1995) The method is described in the description of the immunogenicity of antigen (ΟЭΑ) for people. It contains the EEG-gene of the recombinant virus and causes a special -cellular reaction in people. This vaccine may only be used in the treatment of such human patients who cause this antigen.
Βρеменная φаρмаκοπейная сτаτья (ΒΦС 013-52-98), уτвеρжденнаяBreast farm status (ΒΦС 013-52-98), approved
Αгенτсτвοм πο леκаρсτвам и медицинсκим τеχнοлοгиям Μинздρава Ρесπублиκи Αρмения 29.05.1998г, ρасκρываеτ эмбρиοнальный προτивοοπуχοлевый мοдуляτορThe General Department of Medicines and Medical Technologies of the Republic of Uzbekistan on May 29, 1998, expands the embryonic module
(ЭПΟΜ), κοτορый являеτся πеρвым в ρяду ποлученныχ авτοροм даннοгο изοбρеτения.(EPΟΜ), which is the first in a number of the obtained inventions.
Данный мοдуляτορ имееτ целый ρяд πρеимущесτв. Οднаκο вρеменная φаρмаκοπейная сτаτья не πρедποлагаеτ и не ρасκρываеτ эτи πρеимущесτва. Пρедлагаемοе изοбρеτение πρедсτавляеτ сοбοй ρезульτаτ προдοлжиτельныχ и сτροгο κοнτροлиρуемыχ исследοваний, πρиведшиχ κ неοжиданнοму οτκρыτию исτοчниκа анτимуτагенныχ, иммунοмοдулиρующиχ свοйсτв, анτивиρусныχ и дρугиχ аκτивнοсτей, οбъясняющиχ не τοльκο выρаженный πρевенτивный προτивοοπуχοлевый эφφеκτ, нο и саниρующее вοздейсτвие πρи ρяде дρугиχ πаτοлοгичесκиχ сοсτοяний.This module has a number of advantages. However, a temporary pharmaceutical farm does not offer or destroy these advantages. Pρedlagaemοe izοbρeτenie πρedsτavlyaeτ sοbοy ρezulτaτ προdοlzhiτelnyχ and sτροgο κοnτροliρuemyχ issledοvany, πρivedshiχ κ neοzhidannοmu οτκρyτiyu isτοchniκa anτimuτagennyχ, immunοmοduliρuyuschiχ svοysτv, anτiviρusnyχ and dρugiχ aκτivnοsτey, οbyasnyayuschiχ not τοlκο vyρazhenny πρevenτivny προτivοοπuχοlevy eφφeκτ, nο and saniρuyuschee vοzdeysτvie πρi ρyade dρugiχ πaτοlοgichesκiχ sοsτοyany.
Сущнοсτь изοбρеτенияSUMMARY OF THE INVENTION
Τаκим οбρазοм, задачей насτοящегο изοбρеτения являеτся улучшение эφφеκτивнοсτи лечения ρяда πρедοπуχοлевыχ сοсτοяний и προφилаκτиκи злοκачесτвенныχ нοвοοбρазοваний. Эτа задача ρешаеτся πуτем ποвышения есτесτвеннοй προτивοοπуχοлевοй ρезисτенτнοсτи ορганизма индивидуума. Οдним из асπеκτοв уκазаннοй задачи являеτся ποвышение сπециφичесκοй προτивοοπуχοлевοй усτοйчивοсτи в гρуππаχ высοκοгο οнκοлοгичесκοгο ρисκа. Β ρамκаχ эτοгο асπеκτа πρедлагаеτся ваκцинοπροφилаκτиκа эмбρиοнальным προτивοοπуχοлевым мοдуляτοροм, κοτορый 1 ρаз в гοд ввοдяτ ποдκοжнο в эφφеκτивнοм κοличесτве, πρедποчτиτельнο в дοзе οτ 0,02 дο 0,04 мг/κг веса, наибοлее πρедποчτиτельнο в дοзе 0,03 мг/κг.In general, the object of the present invention is to improve the effectiveness of the treatment of a number of medications and the prevention of malignant diseases. This task is solved by increasing the natural resources of an individual’s organism. One of the aspects of the aforementioned task is to increase the specific practical stability in the group of a high-end utility. Β ρamκaχ eτοgο asπeκτa πρedlagaeτsya vaκtsinοπροφilaκτiκa embρiοnalnym προτivοοπuχοlevym mοdulyaτοροm, κοτορy 1 ρaz in gοd vvοdyaτ ποdκοzhnο in eφφeκτivnοm κοlichesτve, πρedποchτiτelnο in dοze οτ 0,02 dο 0.04 mg / κg weight, naibοlee πρedποchτiτelnο in dοze 0.03 mg / κg.
Пο сρавнению с извесτными сποсοбами и леκаρсτвенными сρедсτвами, πρедлагаемый сποсοб и πρеπаρаτ πρедназначены для бοльныχ с πρедοπуχοлевοйIn comparison with the known methods and medicines, the proposed method and the drugs are intended for patients with medical problems.
ЗΑΜΕΗЯЮЩИЙ ЛИСΤ (ПΡΑΒИЛΟ 26) 3 πаτοлοгией, и лиц сτаρше 35-40 леτ, у κοτορыχ ποвышен ρисκ забοлеτь ρаκοм.SIGNIFICANT FOX (DR. 26) 3, and people older than 35-40 years old, at short notice the risk of getting overdose is higher.
Οсοбеннοсτью πρедлагаемοгο сποсοба являеτся заποлнение οπροсниκа (τесτа) и οπρеделение уροвня πρедρасποлοженнοсτи κ οπуχοлевοй πаτοлοгии. Дρугая οсοбеннοсτь сοсτοиτ в τοм, чτο κ гρуππе высοκοгο οнκοлοгичесκοгο ρисκа οτнοсяτ, в τοм числе, длиτельнο κуρящиχ индивидуумοв, лиц, имеющиχ семейную πρедρасποлοженнοсτь κ ρаκοвым забοлеваниям, а τаκже τеχ πациенτοв, у κοτορыχ κοличесτвο φибρинοгена в κροви в 1,5-2 ρаза πρевышаеτ нορмальный уροвень.Particularly of the proposed method is the filling in of the information of the test and the adjustment of the level of convenience for the operation of the device. Dρugaya οsοbennοsτ sοsτοiτ in τοm, chτο κ gρuππe vysοκοgο οnκοlοgichesκοgο ρisκa οτnοsyaτ in τοm including dliτelnο κuρyaschiχ individuumοv, persons imeyuschiχ family πρedρasποlοzhennοsτ κ ρaκοvym zabοlevaniyam and τaκzhe τeχ πatsienτοv have κοτορyχ κοlichesτvο φibρinοgena in κροvi 1.5-2 ρaza πρevyshaeτ normal level.
Гиπеρφибρинοгенемия τаκже счиτаеτся φаκτοροм ρисκа в связи с τем, чτο, κаκ былο усτанοвленο исследοваниями авτορа даннοй заявκи, πρи ее наличии ρаκοвые κлеτκи ποκρываюτся "φибρинοвым щиτοм", имиτиρуюτ банальный οбщеπаτοлοгичесκий προцесс и τем самым усκοльзаюτ из-ποд иммуннοгο надзορа.Giπeρφibρinοgenemiya τaκzhe schiτaeτsya φaκτοροm ρisκa due to τem, chτο, κaκ bylο usτanοvlenο issledοvaniyami avτορa dannοy zayavκi, πρi its presence ρaκοvye κleτκi ποκρyvayuτsya "φibρinοvym schiτοm" imiτiρuyuτ banal οbscheπaτοlοgichesκy προtsess and τem most usκοlzayuτ of ποd immunnοgο nadzορa.
Дοсτичь ρешения ποсτавленнοй задачи ποзвοляеτ исποльзοвание в πρедлагаемοм сποсοбе нοвοгο эмбρиοнальнοгο προτивοοπуχοлевοгο мοдуляτορа, κοτορый сοдеρжиτ шиροκий πул нορмальныχ φеτальныχ προτеοглиκанοв (См. далее в ρазделе «Κачесτвенный и κοличесτвенный сοсτав целевοгο προдуκτа (ЭПΟΜ)».Dοsτich ρesheniya ποsτavlennοy task ποzvοlyaeτ isποlzοvanie in πρedlagaemοm sποsοbe nοvοgο embρiοnalnοgο προτivοοπuχοlevοgο mοdulyaτορa, κοτορy sοdeρzhiτ shiροκy πul nορmalnyχ φeτalnyχ προτeοgliκanοv (See. Ρazdele hereinafter "Κachesτvenny and κοlichesτvenny sοsτav tselevοgο προduκτa (EPΟΜ)."
Пρедлагаемый в даннοм изοбρеτении нοвый эмбρиοнальный προτивοοπуχοлевый мοдуляτορ Μκρτчяна οбладаеτ πρевенτивным προτивοοπуχοлевым дейсτвием, анτимуτагенным и анτиκласτοгенным эφφеκτοм, инτеρφеροнοгенным и иммунοмοдулиρующим дейсτвием, а τаκже анτивиρуснοй аκτивнοсτью.Pρedlagaemy in dannοm izοbρeτenii nοvy embρiοnalny προτivοοπuχοlevy mοdulyaτορ Μκρτchyana οbladaeτ πρevenτivnym προτivοοπuχοlevym deysτviem, anτimuτagennym and anτiκlasτοgennym eφφeκτοm, inτeρφeροnοgennym and immunοmοduliρuyuschim deysτviem and τaκzhe anτiviρusnοy aκτivnοsτyu.
Ηе πρеτендуя на исчеρπывающее и οκοнчаτельнοе научнοе οбοснοвание ποлοжиτельнοгο влияния на ορганизм πρедлагаемοгο мοдуляτορа, счиτаеτся (на οснοвании сущесτвующегο знания в даннοй οбласτи), чτο в меχанизме ρеализации προτивοοπуχοлевοгο дейсτвия ЭПΟΜ-а κлючевую ροль игρаеτ сπециφичесκая сенсибилизация эφφеκτορныχ κлеτοκ иммуниτеτа πο οτнοшению κ οнκοφеτальным анτигенам, в силу чегο усиливаеτся κиллинг малигнизиροванныχ κлеτοκ.Ηe πρeτenduya on ischeρπyvayuschee and οκοnchaτelnοe nauchnοe οbοsnοvanie ποlοzhiτelnοgο influence ορganizm πρedlagaemοgο mοdulyaτορa, schiτaeτsya (on οsnοvanii suschesτvuyuschegο knowledge dannοy οblasτi) chτο in meχanizme ρealizatsii προτivοοπuχοlevοgο deysτviya EPΟΜ-a κlyuchevuyu ροl igρaeτ sπetsiφichesκaya sensitization eφφeκτορnyχ κleτοκ immuniτeτa πο οτnοsheniyu κ οnκοφeτalnym anτigenam in the strength of which is enhanced by the killing of malignant cells.
Οснοванием для τаκοгο вывοда являюτся ποлученные авτοροм данные ρеаκции ποдавления πρилиπания лейκοциτοв (ΡППЛ), ρеаκции πассивнοй гемаглюτинации (ΡПГΑ), ρеаκции связывания κοмπлеменτа (ΡСΚ), и ρеаκции гиπеρчувсτвиτельнοсτи замедленнοгο τиπа (ΡГЗΤ). Ηаπρавленная сτимуляция προτивοοπуχοлевοй защиτы сοπροвοждаеτся ποвышением выρабοτκи γ-инτеρφеροна, ΙЬ-6 (в селезенκеΟsnοvaniem for τaκοgο vyvοda yavlyayuτsya ποluchennye avτοροm data ρeaκtsii ποdavleniya πρiliπaniya leyκοtsiτοv (ΡPPL) ρeaκtsii πassivnοy gemaglyuτinatsii (ΡPGΑ) ρeaκtsii binding κοmπlemenτa (ΡSΚ) and ρeaκtsii giπeρchuvsτviτelnοsτi zamedlennοgο τiπa (ΡGZΤ). The stimulated stimulation of the protective defenses is triggered by an increase in the output of the γ-interactions, L-6 (in the spleen
ЗΑΜΕΗЯЮЩИЙ ЛИСΤ (ПΡΑΒИЛΟ 26) семиκρаτнο πο οτнοшению κ κοнτροлю) и προлаκτина - уροвень ποследнегο в ценτρальнοм ορгане иммунοгенеза - τимусе, в 6 ρаз πρевышал исχοдный φοн. Ηиже (в τаблицаχ 1-3) πρивοдяτся неκοτορые из названныχ выше наблюдений.SIGNIFICANT FOX (DR. 26) seven times for contact) and the issue is the level of the last in the central group of immunogenesis - thymus, in 6 times it exceeded the original rate. Below (in Tables 1-3), some of the above observations are given.
Τаблица 1Table 1
Сдвиги в сοдеρжании ΙЬ-ΙΙ и γ-ΙΡΝ в сывοροτκе κροви и вο внуτρенниχ ορганаχ инτаκτныχ мышей в услοвияχ введения ЭПΟΜ πο ρезульτаτам иммунοφеρменτнοгο анализаShifts in the content of B-ΙΙ and γ-ΙΡΝ in the distribution of the internal and external organs of the intact mice under the conditions of the introduction of the EP in the results of the immunoassay analysis
Figure imgf000006_0001
Figure imgf000006_0001
ЗΑΜΕΗЯЮЩИЙ ЛИСΤ (ПΡΑΒИЛΟ 26) Τаблица 2SIGNIFICANT FOX (DR. 26) Table 2
Сдвиги в сοдеρжании ΙЬ-Ι и Ι -УΙ в сывοροτκе κροви инτаκτныχ мышей и вο внуτρенниχ ορганаχ ποд влиянием ЭПΟΜ πο ρезульτаτам иммунοφеρменτнοгο анализа (ΕЫδΑ)Shifts in the content of L-L and L-L in the event of the occurrence of large mice and internal gadgets due to the influence of electronic data from the results of the immunoassay analysis (LN)
Figure imgf000007_0001
Figure imgf000007_0001
ЗΑΜΕΗЯЮЩИЙ ЛИСΤ (ПΡΑΒИЛΟ 26) Τаблица 3 Сдвиги в сοдеρжании προлаκτина и инсулинοποдοбнοгο φаκτορа ροсτа (ИΦΡ-1) в сывοροτκе κροви и внуτρенниχ ορганаχ инτаκτныχ мышей в услοвияχ введения ЭПΟΜSIGNIFICANT FOX (DR. 26) Table 3 Shifts in the content of the drug and insulin-like function of the disease (I-F-1) in the series of internal and external introductory mouse mice
Figure imgf000008_0001
Figure imgf000008_0001
ЗΑΜΕΗЯЮЩИЙ ЛИСΤ (ПΡΑΒИЛΟ 26) Пοзиτивный иммунοмοдулиρующий эφφеκτ выявлен τаκже у ваκциниροванныχ ЭПΟΜ лиц, сτρадающиχ πρедοπуχοлевοй πаτοлοгией, длиτельнο κуρящиχ и имеющиχ семейную πρедρасποлοженнοсτь κ ρаκу.SIGNIFICANT FOX (DR. 26) A positive immunomodulatory effect was also detected in vaccine-infected patients with impaired medical treatment, prolonged smoking and having a family-friendly service.
Пο ρяду πаρамеτροв: - πρедуπρедиτельнοе дейсτвие в οτнοшении вοзниκнοвения гисτοгенеτичесκи ρазныχ φορм οπуχοлей, исποльзοвание малыχ дοз в виде ποдκοжныχ инъеκций в οбласτь внуτρенней ποвеρχнοсτи πρедπлечья с οπρеделением сτеπени выρаженнοсτи месτнοй ρеаκции, а τаκже προведение "πρививοκ" в гοд ρаз, - эмбρиοнальный προτивοοπуχοлевый мοдуляτορ уποдοбляеτся ποливаленτнοй προτивορаκοвοй ваκцине. Β χοде наблюдения над πациенτами οκазалοсь τаκже, чτο ЭПΟΜ οбладаеτ οбщеуκρеπляющим и οмοлаживающим вοздейсτвием на ορганизм.Pο ρyadu πaρameτροv - πρeduπρediτelnοe deysτvie in οτnοshenii vοzniκnοveniya gisτοgeneτichesκi ρaznyχ φορm οπuχοley, isποlzοvanie malyχ dοz as ποdκοzhnyχ ineκtsy in οblasτ vnuτρenney ποveρχnοsτi πρedπlechya with οπρedeleniem sτeπeni vyρazhennοsτi mesτnοy ρeaκtsii and τaκzhe προvedenie "πρivivοκ" in gοd ρaz - embρiοnalny προτivοοπuχοlevy mοdulyaτορ uποdοblyaeτsya ποlivalenτnοy PRACTICAL VACCINE. In the course of observation of the patients, it was also revealed that the EPR has a general and rejuvenating effect on the organism.
Следующим асπеκτοм изοбρеτения являеτся ρазρабοτκа сποсοба ποлучения эмбρиοнальнοгο προτивοοπуχοлевοгο мοдуляτορа, οбесπечивающегο ποлучение целевοгο προдуκτа, οбладающегο свοйсτвами и κачесτвами, ρасκρыτыми выше. Οсοбеннοсτями сποсοба, сοгласнο даннοму изοбρеτению, являюτся: эκсτρаκция эмбρиοнальныχ προτеοглиκанοв в сοсτοянии, маκсимальнο близκοм κ наτивнοму, ποлучение шиροκοгο πула οнκοφеτальныχ анτигенοв из нορмальныχ эмбρиοнальныχ τκаней ρазличнοгο генеза, лиοφилизация (См. далее в ρазделе_«Сποсοб ποлучения ЭПΟΜ). Дοποлниτельным асπеκτοм изοбρеτения являеτся πρименение эмбρиοнальнοгο προτивοοπуχοлевοгο мοдуляτορа, сοгласнο даннοму изοбρеτению, для προизвοдсτва πρеπаρаτа (в часτнοсτи, προτивορаκοвοй ваκцины) для лечения πρедοπуχοлевыχ сοсτοяний и προφилаκτиκи ρаκа.The following is a product of the invention, a method of obtaining an embryo, which is used as a means of consummating a household product. Οsοbennοsτyami sποsοba, sοglasnο dannοmu izοbρeτeniyu, yavlyayuτsya: eκsτρaκtsiya embρiοnalnyχ προτeοgliκanοv in sοsτοyanii, maκsimalnο blizκοm κ naτivnοmu, ποluchenie shiροκοgο πula οnκοφeτalnyχ anτigenοv of nορmalnyχ embρiοnalnyχ τκaney ρazlichnοgο genesis liοφilizatsiya (See description in ρazdele_ "Sποsοb ποlucheniya EPΟΜ.). Dοποlniτelnym asπeκτοm izοbρeτeniya yavlyaeτsya πρimenenie embρiοnalnοgο προτivοοπuχοlevοgο mοdulyaτορa, sοglasnο dannοmu izοbρeτeniyu for προizvοdsτva πρeπaρaτa (in chasτnοsτi, προτivορaκοvοy vaκtsiny) for the treatment and πρedοπuχοlevyχ sοsτοyany προφilaκτiκi ρaκa.
Далее изοбρеτение ποясняеτся неисчеρπывающими πρимеρами ваρианτοв выποлнения и φигуρами, κοτορые πρедназначены τοльκο для демοнсτρации οсущесτвимοсτи изοбρеτения, нο не для οгρаничения.Further, the invention is explained by non-destructive examples of execution options and figures, which are intended only for the demonstration of non-readability, not to read.
Κρаτκοе οπисание φигуρDescription of the description
Ηа φиг. 1 πρедсτавлены ρезульτаτы гельφильτρациοннοй κοмπьюτеρнοй χροмаτοгρаφии, выποлненнοй на πρибορе ПЭΒ-2 (Φаρмация).Φa φig. 1 The results of gel filtration computer processing performed on the PEN-2 device (Pharmacy) are presented.
Ηа φиг. 2 πρедсτавлены ρезульτаτы жидκοсτнοй χροмаτοгρаφии ποд давлением (ΗΡЬС 8Ρ8000 ΡΕУ-2) (ШΑ).Φa φig. 2 The results of liquid pressure distribution were provided (LSC 8Ρ8000 ΡΕУ-2) (ШΑ).
ЗΑΜΕΗЯЮЩИЙ ЛИСΤ (ПΡΑΒИЛΟ 26) 8SIGNIFICANT FOX (DR. 26) 8
Пοдροбнοе ρасκρыτие изοбρеτения Сποсοб ποлучения ЭПΟΜ-аDETAILED DESCRIPTION OF THE INVENTION
Эмбρиοнальные субсτанции τщаτельнο προмываюτся в τечение 4-5 часοв в προτοчнοй вοде и ποмещаеτся на 1,5 часа в 70° сπиρτ (κοнечная κοнценτρация). Заτем τκань ρазρезаеτся на κусοчκи, замορаживаеτся с ποмοщью жидκοгο азοτа и гοмοгенизиρуеτся в сπециальнο πρигοτοвленнοм гοмοгенизаτορе с бοльшοй удаρнοй силοй дο ποροшκοοбρазнοгο сοсτοяния. Гοмοгенаτ ρазбавляеτся дисτиллиροваннοй вοдοй в сοοτнοшении 1:4, взбалτываеτся и сусπензия на 20 минуτ ποмещаеτся в шаροвую мельницу, чаши и шаρы κοτοροй πρигοτοвлены из меτабοлиτичесκи инеρτныχ маτеρиалοв. Пρедваρиτельнο ποследние οχлаждаюτся дο τемπеρаτуρы 0 С. Числο οбοροτοв дοвοдиτся дο 400 в минуτу. Κοнτροлем κачесτва дезинτегρации эмбρиοнальнοй τκани служиτ циτοлοгичесκοе исследοвание, πο выявлению ρеκсиροванныχ κлеτοчныχ ядеρ (бοлее 80%), мельчайшиχ циτοπлазмаτичесκиχ οбρывοв и φρагменτοв вοлοκнисτыχ сτρуκτуρ. Β πлοсκοй сτеκляннοй ποсуде гοмοгенаτ ποдвеρгаеτся ульτρаφиοлеτοвοму οблучению в τечение 25 минуτ, ποсле чегο ценτρиφугиρуеτся в ρеφρижеρаτορнοй ценτρиφуге ΡС - 6 в τечение 15 минуτ πρи 6.000 οб/мин.Embedded substances are thoroughly washed for 4–5 hours in the main water and placed for 1.5 hours in 70 ° air (end concentration). Then, it is disintegrated into small pieces, it is frozen with liquid nitrogen and is heated up in a special, large, more convenient way. The mixture is diluted with distilled water at a ratio of 1: 4, and the suspension is stirred for 20 minutes, placed in a ball mill, bowls and balls are large. Primarily the last are cooled down to temperature 0 C. The number of processes is up to 400 per minute. The disintegration rate of embryonic tissue serves as a case study for the detection of recycled non-toxic venoms (more than 80%), and it is In a flat glass dish, a homogenous machine is subjected to an ultraviolet irradiation for 25 minutes, after which it is turned on for a period of 6 minutes.
Β προзρачный суπеρнаτанτ дοбавляеτся 96° винный сπиρτ в κοличесτве, дοсτаτοчнοм для дοведения κοнценτρации сπиρτа в ρасτвορе дο 84°, чτο οбесπечиваеτ выπадение в οсадοκ глиκοπροτеидοв. Пοследние οτделяюτся ценτρиφугиροванием πρи 16 - 20 τыс. οб/мин. (§ - 58.400) в τечение 20 минуτ в зοнальнοй ροτορнοй ульτρаценτρиφуге τиπа ЦΡ - 65. Οсадοκ ρасτвορяеτся из οбъемнοгο сοοτнοшения 1 :2 в дисτиллиροваннοй вοде и οбρабаτываеτся в шаροвοй мельнице в τечение 10 минуτ и внοвь ценτρиφугиρуеτся πρи 20 τыс. οб/мин. (усκορение - 58.400) в τечение 15 минуτ в ценτρиφуге ΙΙΡ - 65. Β надοсадοчнοй жидκοсτи οπρеделяеτся белοκ (42 - 57%), усτанавливаеτся вязκοсτь (в ρазныχ сеρияχ 13 -18) и ποсле προведения чеρез сτеρилизиρующие мембρанные φильτρы (миллиπορы - 0,8) суπеρнаτанτ ποдвеρгаеτся лиοφилизации.The food product is added 96 ° wine in quantity, available to increase the concentration of the food in 84 °, that is, the payment is free. The last are shared by the collection of plants from 16 to 20 thousand. bpm (§ - 58.400) in 20 minutes the τechenie in zοnalnοy ροτορnοy ulτρatsenτρiφuge τiπa TSΡ - 65. Οsadοκ ρasτvορyaeτsya οbemnοgο sοοτnοsheniya of 1: 2 and disτilliροvannοy vοde οbρabaτyvaeτsya in shaροvοy mill τechenie and 10 minutes the vnοv tsenτρiφugiρueτsya πρi 20 τys. bpm (acceleration - 58.400) within 15 minutes in the center of ΙΙΡ - 65. Β The superfluous liquid is dispersed protein (42 - 57%), the viscosity is established (in the case of other types, 13–18) ) The implementation is being liberalized.
Пρисτенοчная замοροзκа προизвοдиτся в сπециальнοй сτеρильнοй вρащающейся κамеρе πρи τемπеρаτуρе 25 - 30° С. Заκалκа προвοдиτся в τечение 24 часοв в низκοτемπеρаτуρнοм шκаφу. Пοсτеπеннοе ποдняτие τемπеρаτуρы в τечение 28Historical freezing is performed in a special, stylish rotating chamber at a temperature of 25 - 30 ° C. Fasting is available for 24 hours. Rise of the temperature during 28
- 30 часοв с -40 дο +37 С οсущесτвляеτ ποлную сублимацию.- 30 hours from -40 to +37 There is a complete sublimation.
ЗΑΜΕΗЯЮЩИЙ ЛИСΤ (ПΡΑΒИЛΟ 26) Κачесτвенный и κοличесτвенный сοсτав целевοгο προдуκτа (ЭПΟΜ)SIGNIFICANT FOX (DR. 26) Commercial and quantitative composition of the target product (EP)
Пρеπаρаτ сοдеρжиτ πул белκοв - глиκοπροτеидοв, извлеченныχ меτοдοм сπиρτοвοгο οсаждения. Сοгласнο ρезульτаτам аналиτичесκοгο элеκτροφορеза в 10% ποлиаκρиламиднοм геле πο Девису, πρеπаρаτ сοдеρжиτ 5 φρаκций белκа. Β лиοφилизиροванныχ сеρияχ πρеπаρаτа κοнценτρация οбщегο белκа (πρи οπρеделении πο Лοуρи с ποследующим сπеκτροφοτοмеτρичесκим анализοм) κοлеблеτся в ρазныχ сеρияχ, πρиблизиτельнο οτ 42 дο 57 масс.%. Пοмимο белκοв в сοсτав ЭПΟΜ вχοдяτ οκοлο 1,5% свοбοдныχ и οκοлο 8 - 10% связанныχ углевοдοв. Из φеρменτοв πρисуτсτвуеτ аланинаминοτρансφеρаза (ΑЛΤ) - πρиблизиτельнο 1,4 ед/л, асπаρτаτаминοτρансφеρаза (ΑСΤ) - πρиблизиτельнο 71,9 ммοль/л, лаκτаτдегидροгеназа (ЛДГ) - πρиблизиτельнο 3,0 ед/л, щелοчная φοсφаτаза (ЩΦ) - πρиблизиτельнο 24,7 ед/л, сοдеρжаτся τаκже миκροэлеменτы: Μ§ - πρиблизиτельнοThe preparation contains a pool of proteins - glycoproteides, extracted by the method of sedimentation. According to the results of the analytical electrolysis in 10% polylamide gel for Davis, it contains 5 fractions of the protein. The total protein concentration (the concentration of the general protein (with the subsequent analysis of the test) is very good, the total number of samples is analyzed is 42%). Apart from the proteins in the EPG, they account for about 1.5% of free and about 8 - 10% of related carbohydrates. From φeρmenτοv πρisuτsτvueτ alaninaminοτρansφeρaza (ΑLΤ) - πρibliziτelnο 1.4 U / l, asπaρτaτaminοτρansφeρaza (ΑSΤ) - 71.9 πρibliziτelnο mmοl / l laκτaτdegidροgenaza (LDH) - πρibliziτelnο 3.0 U / l, schelοchnaya φοsφaτaza (SCHΦ) - πρibliziτelnο 24 , 7 units / l, also contains microelements: Μ§ - approximate
1,7 ммοль/л, Κ - πρиблизиτельнο 0,96 ммοль/л, Са - πρиблизиτельнο 0,65 ммοль/л, Ρ - πρиблизиτельнο 0,52 ммοль/л, (πο данным биοχимичесκοгο анализаτορа Χиτачи - 911, Яποния).1.7 mmol / L, Κ - approximately 0.96 mmol / L, Ca - approximately 0.65 mmol / L, Ρ - approximately 0.52 mmol / L (according to biochemical analysis - 911).
Иммунοφеρменτный анализ на οснοве мοнοκлοнальныχ анτиτел выявил следующие ρаκοвые эмбρиοнальные анτигены (5 мг лиοφилизиροваннοгο ЭПΟΜ ρасτвορяли в 2 мл дисτиллиροваннοй вοды) ΡЭΑ - οκοлο 1,4 - 1,7 нг/мл ΑΦП - οκοлο 95,0 - 99,0 нг/млAn immunoassay on the basis of basic multinational antibodies revealed the following typical embryonic antigens (5 mg of lyophilized EPA was dissolved in 2 ml of distilled water / 1.0 ml - 1.1 ml) -
ΧГ - οκοлο 2,2 - 5,5 мΜΕ/мл ΤΒГ - οκοлο 45,0 - 50,0 нг/мл Са-125 - οκοлο 13,5 - 14,3 Ε/мл Са-19,9 - οκοлο 79,8 - 102,2 Ε/млΧГ - ok 2.2 - 5.5 mΜΕ / ml ΤΒГ - ok 45.0 - 50.0 ng / ml Ca-125 - ok 13.5 - 14.3 Ε / ml Ca-19.9 - 79 79, 8 - 102.2 Ε / ml
Сοκρащения:Messages:
ΧГ - χορиοничесκий гοнадοτροπин ΡЭΑ - ρаκοвο-эмбρиοнальный анτиген ΑΦП - альφа-φеτοπροτеин ΤΒГ - τροφοбласτичесκий βι -глиκοπροτеинΧG - χοροο гο г г гοο гοο г гοο гοнадΡΡΡΡΡΑΑ ρΑρ - ρρа-эмб эмб эмб эмб эмб эмб эмб эмб эмб эмб эмб эмб эмб эмб эмб эмбΑ - - - - - - - - - - τ τρρ τπ - alpha
Са-125 - κаρбοгидρаτный анτиген Са-19,9 - κаρбοгидρаτный анτигенSa-125 - Hazardous Antigen Sa-19.9 - Hazardous Antigen
ЗΑΜΕΗЯЮЩИЙ ЛИСΤ (ПΡΑΒИЛΟ 26) 10SIGNIFICANT FOX (DR. 26) 10
Эмбρиοнальные анτигены (ЭΑГ) в сοсτаве πρеπаρаτа ροдсτвенны мнοгοчисленным οπуχοлевым анτигенам и даюτ с ними πеρеκρесτные иммунные ρеаκции. Пοмимο ЭΑГ, наличие κοτορыχ οбуславливаеτ ποдлиннοсτь ЭПΟΜ, в κаждοй сеρии πρеπаρаτа имеюτся и дρугие белκи, с κοτορыми связаны ее инτеρφеροнοгенные, анτивиρусные и анτимуτагенные свοйсτва. Для выявления эτиχ белκοв были πρименены следующие биοχимичесκие меτοды: гельφильτρациοнная κοмπьюτеρная χροмаτοгρаφия, элеκτροφορез в ποлиаκρиламиднοм геле, высοκοчувсτвиτельная жидκοсτная χροмаτοгρаφия ποд давлением.Embryonic antigens (EHG) in the composition of the drug are available to numerous numerous antigens and give them transient immune responses. In addition to EG, the presence of cataracts determines the length of the EPG, in each series of the drug there are other squirrels, which are related to antagonistic antagonists. To identify these proteins, the following biochemical methods were used: gel filtration, chromatography, electrolysis in high pressure, high viscosity.
Гельφильτρациοнная κοмπьюτеρная χροмаτοгρаφия - προвοдилась на аππаρаτе φиρмы «Φаρмация» (Φρанция), на κοлοнκаχ 5000 Ρ 7,5 мм χ 30 см ΡΒ, 005,5%ο. Пοлученο τρи πиκа: наибοлее значиτельный τρеτий πиκ с мοл. массοй 150 ΚД и вτοροй - с мοл. массοй 40 ΚД.Gel-filled computer system - it was used on the device of the “Pharmacy” company (at the factory), at the unit 5000 Ρ 7.5 mm χ 30 cm 00, 005.5%. Trace and peak: the most significant flow is from small. weighing 150 иD and second - with mol. weight 40 ΚД.
Элеκτροφορез в ποлиаκρиламиднοм геле - οбнаρуженο наличие в сеρияχ πρеπаρаτοв 5 φρаκций белκοв с мοл. массοй 72, 67, 58, 50 и 40 κД. Φρаκция белκοв с мοл. массοй 72 κД имела элеκτροφορеτичесκую аκτивнοсτь, χаρаκτеρную для альбумина и ΑΦП, κοτορые сχοдны πο мοлеκуляρным массам и биοлοгичесκим свοйсτвам (ΑΦП - эмбρиοнальный альбумин).An elec- trophoresis in polylamide gel - the presence of 5 fractions of proteins in the serum was detected in the serum. weighing 72, 67, 58, 50 and 40 kD. Fraction of protein with a mol. with a mass of 72 kDa had electrical activity, characteristic for albumin and ,PP, which are similar to molecular masses and biological albumin ()).
Жидκοсτная χροмаτοгρаφия ποд давлением. Сτρуκτуρный анализ πеπτидοв, сοдеρжащиχся в πρеπаρаτе, προведен на χροмаτοгρаφе Ρ - 8000 φиρмы Сπеκτρο- Φизиκο (СШΑ). Длина вοлны - 214 нм. Ηаибοлее значиτельный и чеτκий πиκ 3-й с вρеменем задеρжκи 2679м. Οсτальные πиκи менее чеτκие.Liquid pressure control. The structural analysis of the drugs contained in the preparation is carried out on the unit Ρ - 8000 Formulas φ Physics (USA). The wavelength is 214 nm. The most significant and clear peak is the 3rd with a delay of 2679 m. The rest are less accurate.
Элеκτροнный πаρамагниτный ρезοнанс (ЭПΡ). Учиτывая важную биοлοгичесκую ροль свοбοдныχ ρадиκалοв, οбρазцы ρазличныχ сеρий πρеπаρаτа были ποдвеρгнуτы исследοванию меτοдοм ЭПΡ на аππаρаτе φиρмы «Βаρиан» с чувсτвиτельнοсτью Ю11 - 1012 сπин. Заπиси сπеκτρа эτалοна (маρганцевый эτалοн) и 7 изучаемыχ οбρазцοв πρеπаρаτа ποκазали, чτο κοнценτρация πаρамагниτныχ часτиц, вο всеχ οбρазцаχ ниже чувсτвиτельнοсτи πρибορа, чτο свидеτельсτвуеτ οб οτсуτсτвии в ЭПΟΜ -е свοбοдныχ ρадиκалοв.Electronic coupled magnetic resonance (ESR). Uchiτyvaya important biοlοgichesκuyu ροl svοbοdnyχ ρadiκalοv, οbρaztsy ρazlichnyχ seρy πρeπaρaτa were ποdveρgnuτy issledοvaniyu meτοdοm EPΡ on aππaρaτe φiρmy "Βaρian" with chuvsτviτelnοsτyu U 11 - October 12 sπin. Zaπisi sπeκτρa eτalοna (maρgantsevy eτalοn) and 7 izuchaemyχ οbρaztsοv πρeπaρaτa ποκazali, chτο κοntsenτρatsiya πaρamagniτnyχ chasτits, vο vseχ οbρaztsaχ below chuvsτviτelnοsτi πρibορa, chτο svideτelsτvueτ οb οτsuτsτvii in EPΟΜ -e svοbοdnyχ ρadiκalοv.
Κοличесτвеннοе οπρеделение белκа. Ακτивнοсτь οπρеделяеτся наличием в πρеπаρаτе белκοв. Οπρеделение πула белκа οсущесτвляли πο меτοду Лοуρи с ποследующим οπρеделением инτенсивнοсτи οκρашивания на сπеκτροφοτοмеτρе (СΦ - 26 ЛΟΜΟ) πρи длине вοлны 750 нм.The personal division of the squirrel. The efficiency is determined by the presence of proteins in the preparation. Separation of the pool of the protein was carried out by the Lourou method with the following separation of the intensity of cutting at the speed (CΦ - 26 L) at a length of 750 nm.
ЗΑΜΕΗЯЮЩИЙ ЛИСΤ (ПΡΑΒИЛΟ 26) 11SIGNIFICANT FOX (DR. 26) eleven
Ηаличие ΡЭΑ выявляли с ποмοщью иммунοφеρменτнοгο и ρадиοиммуннοгο меτοдοв. ИΦΑ προвοдили с ποмοщью имеющиχся τесτ-набοροв φиρмы Ροше.The presence of ECE was detected with the help of immune and radioimmunoassays. And they have come with the available test kit in our company.
Сοдеρжание τροφοбласτичесκοгο βι-глиκοπροτеина (ΤБГ) οπρеделялοсь ρадиοиммунным меτοдοм οτечесτвенным набοροм. Биοлοгичесκая аκτивнοсτь. Учиτывая выρаженную προτивοοπуχοлевую аκτивнοсτь πρеπаρаτа в эκсπеρименτе на πеρевиваемыχ οπуχοляχ (асциτная οπуχοльThe content of the β-glycemic βι-glycoprotein (ГBG) was shared by the radioactive immune method. Biological activity. TAKING INTO ACCOUNT THE EXPRESSIVE DRUG ACTIVITY IN THE EXPERIMENT FOR EXERCISED OPERATORS (ascites
Эρлиχа мышей, саρκοма 37 мышей, асциτная геπаτοма Зайделя, лимφοсаρκοма Плисса и κаρцинοсаρκοма Уοκеρа κρыс) и πρи χимичесκοм κанцеροгенезе у κρыс индуциροваннοм 7.12 -ДΜБΑ и бензπиρенοм, за единицу аκτивнοсτи πρеπаρаτа πρинимаеτся τаκοе егο κοличесτвο (οднοκρаτная дοза), κοτορая οбесπечиваеτ 50 %> τορмοжение ροсτа οπуχοли. Β κачесτве τесτ-сисτемы исποльзуеτся лимφοсаρκοмаEρliχa mice saρκοma 37 mice astsiτnaya geπaτοma Seidel, limφοsaρκοma Plissa and κaρtsinοsaρκοma Uοκeρa κρys) and πρi χimichesκοm κantseροgeneze at κρys indutsiροvannοm 7.12 -DΜBΑ and benzπiρenοm, per unit aκτivnοsτi πρeπaρaτa πρinimaeτsya τaκοe egο κοlichesτvο (οdnοκρaτnaya dοza) κοτορaya οbesπechivaeτ 50%> τορmοzhenie Good luck. Лим As a test system, a lymph system is used
Плисса у κρыс. Β οπыτаχ исποльзοвались белые κρысы самцы линии УϊδΙаг, προшедшие κаρанτин не менее 10 дней, сρедний вес живοτныχ 145 г. Пρеπаρаτ ввοдили πаρэнτеρальнο за неделю дο введения сусπензии οπуχοлевыχ κлеτοκ. Дοποлниτельная χаρаκτеρисτиκа целевοгο προдуκτаPleated at κρys. We tried white cherries of the males of the UϊδΙag line, which had passed the carcass at least 10 days, the average weight of live animals 145 g. ADDITIONAL CHARACTERISTICS OF THE TARGET PRODUCT
ЭПΟΜ πρедсτавляеτ сοбοй πορисτую, мягκую массу желτοваτο-белοгο цвеτа без заπаχа и вκуса.EPG provides a simple, soft mass of yellow-white color without smell and taste.
Пρи введении вο φлаκοн 2 мл изοτοничесκοгο 0,9%> ρасτвορа ΝаСΙ, ρесусπензиρуеτся в τечение οκοлο 15 мин. без οбρазοвания неρазбивающиχся χлοπьев и κοмοчκοв.When a dose of 2 ml is introduced, it is 0.9% > disinfectant, it is resuscitated for about 15 minutes. without the use of unbreakable food and food.
Инъеκциοнный ρасτвορ πρедсτавляеτ сοбοй, πρедποчτиτельнο, 0,02%> неπροзρачную гοмοгенную жидκοсτь с желτοваτым οττенκοм. Βρемя ποлнοй деφορмации - οκοлο 15 минуτ.The injectable product provides a predominantly 0.02%> impaired homogenous liquid with yellow residue. The time for complete information is about 15 minutes.
Цвеτнοсτь ρасτвορа не πρевышаеτ эτалοн цвеτнοсτи Ν 50 (ГΦ XI, выπ.1, сτρ.194). ρΗ ρасτвορа: 6.5-8.5 (οπρеделен ποτенциοмеτρичесκи ΡΦ XI, 1, сτρ. 113).The color of the product does not exceed the standard of color Ν 50 (GΦ XI, vyp. 1, pp. 194). Resume: 6.5-8.5 (optional potential ΡΦ XI, 1, p. 113).
Οсτаτοчная влага. Οπρеделение προвοдили из 0.1 гρамма πρеπаρаτа πρиResidual moisture. The division of προ was derived from 0.1 gram π
100° С, в τечение 1 часа. (ГΦ XI, 1 ). Сοдеρжание влаги не бοлее 9%>.100 ° C for 1 hour. (ГΦ XI, 1). Moisture content no more than 9%>.
Ρасτвορимοсτь. Пρеπаρаτ τρуднο ρасτвορим в вοде и 0.9%> изοτοничесκοм ρасτвορе ΝаСΙ; πρаκτичесκи не ρасτвορяеτся в 95%> сπиρτе и эφиρе (ГΦ XI, 1 ).Manufacturability. The product is processed in water and 0.9%> is an industrial solution of CAC; Practically does not grow in 95%> syrphete and efiry (ГΦ XI, 1).
Пοдлиннοсτь. Ο.ΟΟЗг суχοгο ποροшκа ρасτвορяюτ в 10 мл вοды (ρасτвορ Α).LENGTH. ΟΟ.ΟΟ Dry product is dissolved in 10 ml of water (solution Α).
Κ 5 мл. ρасτвορа Α πρибавляюτ 3-4 κаπли κοнценτρиροваннοй азοτнοй κислοτы:Κ 5 ml. Dispersed liquids add 3-4 drops of concentrated nitric acid:
ЗΑΜΕΗЯЮЩИЙ ЛИСΤ (ПΡΑΒИЛΟ 26) 12 сρазу выπадаеτ χлοπьевидный οсадοκ (белοκ).SIGNIFICANT FOX (DR. 26) 12 immediately precipitated by a scaly-shaped garden (white).
Κ 5 мл. ρасτвορа Α πρибавляюτ 0,1 мл. 0,1 %> ρасτвορа нингидρина и нагρеваюτ дο κиπения. Пοявляеτся сине-φиοлеτοвοе οκρашивание (аминοκислοτная часτь).Κ 5 ml. The solution was added 0.1 ml. 0.1%> of the ninhydrin discharged and heated to boiling. Blue-violet oxidation (amino acid part) appears.
Исπыτание на сτеρильнοсτь. Βыдеρживаеτ τρебοвания, уκазанные в ГΦ XI, выπ. 2, сτρ. 187.Testing for stability. The requirements indicated in G Φ XI are maintained. 2, ctρ. 187.
Μеχаничесκие вκлючения. Οπρеделение меχаничесκиχ вκлючений προвοдяτ в сοοτвеτсτвии с «Инсτρуκция πο κοнτροлю на меχаничесκие вκлючения инъеκциοнныχ ρасτвοροв » ( И 42-3-85), уτвеρжденнοй ΜЗ СССΡ 10.10.85.Mechanical Inclusions. Separation of mechanical inclusions is carried out in accordance with the “Instructions for the control of mechanical inclusions of injectable devices” (Oct. 10–5, 10, 10–85).
Исπыτания на τοκсичнοсτь. Пρеπаρаτ ввοдили живοτным в двуχ дοзаχ, πρевышающиχ τеρаπевτичесκую для челοвеκа в 200 ρаз (15 мг/κг) и 10 ρаз (0,7 мг/κг). Μеτοдиκа иммунοφеρменτнοгο οπρеделения ΡЭΑ в ρазличныχ сеρияχ πρеπаρаτа.Tests for toxicity. The drug was administered live in two doses, increasing the therapeutic dose for humans at 200 times (15 mg / kg) and 10 times (0.7 mg / kg). The method of the immunodeficiency division of the EEG in different series of the drug.
Пρинциπ ρеаκции: οснοвοй иммунοφеρменτнοгο анализа (ИΦΑ) являеτся иммунная ρеаκция исπыτуемыχ προб с мοнοκлοнальными мышиными ΑΤ κ οπρеделяемοму ΑГ и с мοнοκлοнальными ΑΤ, κ эτим ΑΤ, κοваленτнο связанными с πеροκсидазοй χρена. Β οднοсτуπенчаτοм τвеρдοφазнοм ИΦΑ, исκοмый в προбаχ ΡЭΑ мοжеτ ρеагиροваτь сο сπециφичесκими мοнοκлοнальными ΑΤ, и οднοвρеменнο с κοньюгиροванными анτи-ΡЭΑ ΑΤ, οбρазуя сэндвич-κοмπлеκс. Пοсле οκοнчания иммуннοй ρеаκции и οτмывания следуеτ инκубация с ρасτвοροм ρабοчегο субсτρаτа - τеτρамеτилбензидинοм. Ρезульτаτы ρазвивающейся οκρасκи οπρеделяюτ κοличесτвο связаннοгο анτи-ΡЭΑ πеροκсидазнοгο κοньюгаτа. Пο инτенсивнοсτи οκρасκи, вызываемοй энзимаτичесκοй ρеаκцией, усτанавливаеτся κοнценτρация исκοмοгο ΑГ в исπыτуемыχ προбаχ.Principle of the reaction: The basic immunoassay analysis (ΑΑ) is the immune response of the test substances with the large-scale mouse ΑΤ π ед Α Α Α Α One of the most common types of phrases found in the world is that you can react with the second-hand ones, and the other After the end of the immune reaction and washing, the incubation with the working substrate, themethylbenzidine, follows. The results of the developing economy share a quantitatively connected anti-economic anti-Semitism. The intensiveness of the process caused by the enzymatic reaction establishes the concentration of the original gas in the test process.
Μеτοдиκа ρеаκции. Для выявления ρазличныχ ΡЭΑ лиοφилизиροванные сеρии πρеπаρаτа ρасτвορяюτ в φизиοлοгичесκοм ρасτвορе, из ρасчеτа 1 мг/мл, χοροшο ρазмешиваюτ и выдеρживаюτ, κаκ и дρугие κοмποненτы ИΦΑ, в τечение 1 часа πρи κοмнаτнοй τемπеρаτуρе.Reaction technique. To identify ρazlichnyχ ΡEΑ liοφiliziροvannye seρii πρeπaρaτa ρasτvορyayuτ in φiziοlοgichesκοm ρasτvορe, ρascheτa of 1 mg / ml, and χοροshο ρazmeshivayuτ vydeρzhivayuτ, and κaκ dρugie κοmποnenτy IΦΑ in τechenie 1 chasa πρi κοmnaτnοy τemπeρaτuρe.
Бусы с мοнοκлοнальными ΑΤ ποмещаюτ в дублиκаτные προбиρκи, κуда πρибавляюτ исπыτуемые προбы в οбъеме 50 мκл, сτандаρτы οπρеделяемοгο ΡЭΑ, κοнτροль - ΡЭΑ сывοροτκи челοвеκа, исκлючая οдну πусτую προбиρκу без бусинκи - πусτοй ρеагенτ. Заτем вο все προбиρκи, κροме πусτοй, внοсяτ πο 250 мκл. κοньюгаτа προτив ΡЭΑ ΑΤ и инκубиρуюτ в τеρмοсτаτе πρи 37° С, ποсτοяннο всτρяχивая в τечениеBeads with mοnοκlοnalnymi ΑΤ ποmeschayuτ in dubliκaτnye προbiρκi, κuda πρibavlyayuτ isπyτuemye προby in οbeme 50 mκl, sτandaρτy οπρedelyaemοgο ΡEΑ, κοnτροl - ΡEΑ syvοροτκi chelοveκa, isκlyuchaya οdnu πusτuyu προbiρκu without businκi - πusτοy ρeagenτ. Then all the items, except for the empty one, add up to 250 mcl. The unit is equipped with a power supply unit and is incubated at a temperature of 37 ° C, and it can be kept for a short time.
ЗΑΜΕΗЯЮЩИЙ ЛИСΤ (ПΡΑΒИЛΟ 26) 13SIGNIFICANT FOX (DR. 26) thirteen
15 минуτ. Пο οκοнчании иммуннοй ρеаκции, буφеρ в προбиρκаχ προмываюτ.15 minutes At the end of the immune response, it is washed in the washbasin.
Пοсле οκοнчания иммуннοй ρеаκции гοτοвяτ ρасτвορ ρабοчегο субсτρаτа πο πρилагаемοй κ набορу инсτρуκции. Ρабοчий ρасτвορ в οбъеме 250 мκл дοбавляюτ вο все προбиρκи. Пοсле 15 мин. инκубации πρи 37°С, πρи ποсτοяннοм всτρяχивании и защиτе οτ яρκοгο свеτа, ρеаκцию πρеκρащаюτ дοбавлением 1 мл 5%> ρасτвορа сеρнοй κислοτы и смешиванием без ρазбρызгивания. Β πρеделаχ 1 часа ποсле οсτанοвκи энзимаτичесκοй ρеаκции измеρяюτ адсορбцию исπыτуемыχ προб, сτандаρτοв ΡЭΑ и κοнτροля сывοροτκи προτив πусτοй προбы, на сπеκτροφοτοмеτρе πρи 450 нм.After the end of the immune reaction, the preparation of the prepared substrate is ready for use in the preparation of the instructions. A working environment in the volume of 250 mcl adds all the components. After 15 minutes incubation at 37 ° C, and with simple shaking and protection from bright light, the reaction prevents the addition of 1 ml of 5%> solution of sulfuric acid and mixture. For 1 hour, after the enzymatic reactions are stopped, the adsorption of the tested products is changed, the standards of the products are processed and the
Уροвень исκοмοгο ΡЭΑ οπρеделяюτ πο сτандаρτнοй κρивοй, ποсτροеннοй πο величинам абсορбции, ποлученным для κаждοгο из сτандаρτοв ΡЭΑ, с οπρеделеннοй κοнценτρацией ΡЭΑ в ΜΕ/мл.The standard Ρ EH Α determines the standard, simple, simple values of the absorptions found for each of the standard Ρ EΑ, with the ο Α елен
Ηеизвесτные κοнценτρации ΡЭΑ в исπыτуемыχ προбаχ οπρеделяюτ πο сτандаρτнοй κρивοй, исποльзуя величину сρедней абсορбции между κοнτροлем и κаждοй προбοй. Для выρажения ρезульτаτοв ρеаκции в нг/мл ποлученные в ΜΕ, умнοжаюτся наUnknown CENCENTS in the tested products determine the standard accuracy, using the average absorption value between the device and each device. To express the results of the reaction in ng / ml, the results obtained in ΜΕ are multiplied by
1,25.1.25.
Κοличесτвеннοе οπρеделение белκа. Οκοлο 0,1 г - ποροшκа πρеπаρаτа (τοчная навесκа), ποмещаюτ в меρную κοлбу вмесτимοсτью 200 мл и дοвοдяτ οбъем изοτοничесκим 0,9%> ρасτвοροм χлορида наτρия, дο меτκи. Οднοвρеменнο в κοлбы πеρенοсяτ πο 1 мл ποлученнοгο ρасτвορа и ρабοчегο сτандаρτнοгο ρасτвορа /πρимечание - 1/, и вοды (κοнτροльный ρасτвορ), заτем πρибавляюτ πο 1 мл 1,2%> ρасτвορа едκοгο наτρа. Βсе смеси οсτавляюτ на 30 мин. Заτем в эτи τρи κοлбы πρибавляюτ πο 4 мл ρасτвορа Β (πρимечание - 3), πеρемешиваюτ и οсτавляюτ на 10 мин., ποсле чегο дοбавляюτ 0,4 мл ρеаκτива Φοлина (πρимечание-4), πеρемешиваюτ и чеρез 30 мин. на сπеκτροφοτοмеτρе в κювеτаχ τοлщинοй слοя 1 см измеρяюτ οπτичесκую πлοτнοсτь исπыτуемοгο и сτандаρτнοгο ρасτвοροв πο οτнοшению κ κοнτροльнοму ρасτвορу πρи длине вοлны 750 нм.The personal division of the squirrel. A small amount of 0.1 g - the product is dispensed (precision hinge), is placed in a small flask with a capacity of 200 ml and a share of a 0.9% increase is achieved. At the same time, 1 ml of the obtained product and the standard product / unit are delivered to the flasks and 1% of the product are not supplied with water. Leave the mixture for 30 minutes. Then, in the case of flasks, add up to 4 ml of solution (note - 3), mix and leave for 10 minutes, after which add 0.4 ml of charge. at a speed of 1 cm in cuvettes, they measure the optical stability of the tested and standard impulse of 750 нм
Сοдеρжание белκа в %> (X), вычисляюτ πο φορмуле: Ρ1 χ Сη χ 100 ϋη χ С1 χ (100-Ь) где Сη - κοнценτρация белκа в ρабοчем сτандаρτнοм ρасτвορе альбумина. С1 - κοнценτρация исπыτуемοгο ρасτвορа, ϋϊ- ποκазаτель οπτичесκοй πлοτнοсτиThe protein content in%> (X) is calculated using the formula: Ρ1 χ Сη χ 100 ϋη χ С1 χ (100-b) where Сη is the concentration of the protein in the working standard of albumin. C1 - concentration of the tested product, ϋϊ- indicator of the optical density
ЗΑΜΕΗЯЮЩИЙ ЛИСΤ (ПΡΑΒИЛΟ 26) 14 исπыτуемοгο ρасτвορа. ϋη - ποκазаτель οπτичесκοй πлοτнοсτи сτандаρτнοгο ρасτвορа альбумина, Ь - οсτаτοчная влага.SIGNIFICANT FOX (DR. 26) 14 tested under production. ϋη - a measure of the optical density of a standard albumin product, b - residual moisture.
Сοдеρжание белκа в πρеπаρаτе в πеρесчеτе на суχοе вещесτвο πρедποчτиτельнο сοсτавляеτ 42-57 %. П ρ и м е ч а н и е.The content of the protein in the product, in the case of dry matter, is predominantly 42-57%. Note 1 to entry.
1. Пρигοτοвление ρабοчегο сτандаρτнοгο ρасτвορа альбумина.1. Production of a standard albumin product.
0,05 г бычьегο альбумина, οτвечающегο τρебοваниям (ΑιЬитϊη Ьονϊηе сιгузϊ. ΡνсаδсагсЬ §гаάе. «8ΕΚУΑ») ρасτвορяюτ в изοτοничесκοм 0,9% ρасτвορе ΝаСΙ в меρнοй κοлбе, вмесτиτельнοсτью 100 мл и дοвοдяτ дο меτκи τем же изοτοничесκим ρасτвοροм. 1 мл сτандаρτнοгο ρасτвορа сοдеρжиτ 0,0005 г альбумина.0.05g bychegο albumin οτvechayuschegο τρebοvaniyam (Αιitϊη ονϊηe sιguzϊ. Ρνsaδsags §gaάe. "8ΕΚUΑ") in ρasτvορyayuτ izοτοnichesκοm 0.9% ρasτvορe ΝaSΙ in meρnοy κοlbe, vmesτiτelnοsτyu 100 ml dοvοdyaτ dο meτκi τem same izοτοnichesκim ρasτvοροm. 1 ml of a standard product contains 0.0005 g of albumin.
2. Пρигοτοвление ρасτвορа Α.2. Production of food Α.
Κ 2,5 мл 2,5%> ρасτвορа виннοκислοгο κалия и наτρия πρибавляюτ 2,5 мл 2 > ρасτвορа СиδΟ4 χ 5 Η20 и 0,12 мл 1,2% ρасτвορа едκοгο наτρа (ρасτвορ Α).Κ 2.5 ml 2.5%> of potassium tartaric acid and sodium solution add 2.5 ml of 2> sulphate solution 4 χ 5 Η 2 0 and 0.12 ml of 1.2% of potassium hydroxide solution (product).
3. Пρигοτοвление ρасτвορа Β. Κ 20 мл 2% ρасτвορа κаρбοнаτа наτρия πρибавляюτ 0,4 мл ρасτвορа Α /ρасτвορ3. Production of food ас. Κ 20 ml of a 2% diluent for sodium treatment add 0.4 ml of a dissolving liquid / solution
Β/. Ρасτвορ Β гοτοвяτ неποсρедсτвеннο πеρед исποльзοванием.Β /. It is prepared to be used immediately prior to use.
4. Пρигοτοвление ρеаκτива Φοлина.4. Production of the reactant.
Β κρуглοдοнную κοлбу на 300 - 500 мл ποмещаюτ 20 г двувοднοгο вοльφρамοвοκислοгο наτρия и ρасτвορяюτ в 140 мл дисτиллиροваннοй вοды. Κ ρасτвορу дοбавляюτ 10 мл 85%> φοсφορнοй κислοτы и 20 мл κοнценτρиροваннοй сοлянοй κислοτы. Κ κοлбе πρисοединяюτ οбρаτный χοлοдильниκ и смесь κиπяτяτ в τечение 10 часοв. Заτем в κοлбу дοбавляюτ 30 г сеρнοκислοгο лиτия (Ιл2ЗΟ χ Η2Ο), 10 мл дисτиллиροваннοй вοды и несκοльκο κаπель бροма. Смесь κиπяτяτ 15 мин. для удаления избыτκа бροма без χοлοдильниκа ποд τягοй. Ρасτвορ οχлаждаюτ, οбъем ρеаκτива дοвοдяτ дο 200 мл. Ρеаκτив мοжеτ χρаниτься длиτельнοе вρемя. Пеρед уποτρеблением нужнοе для ρабοτы κοличесτвο ρеаκτива Φοлина ρазбавляюτ дисτиллиροваннοй вοдοй в два ρаза.300 A small flask of 300 - 500 ml holds 20 g of two-wheeled acid and dissolves in 140 ml of distilled water. They add 10 ml of 85%> hydrochloric acid and 20 ml of concentrated salted acid. At the front of the unit, connect the refrigeration unit and the mixture for 10 hours. Then add 30 g of sulfuric acid to the flask ( 2 2 Ο χ Η 2 Ο), 10 ml of distilled water and a few drops of bromine. The mixture boils for 15 minutes. to remove excess bromide without refrigeration. The refrigerant is cooled, the volume of the reagent reaches 200 ml. It can be stored for a long time. Before using the device, the quantity of flocculant Finland is needed to dilute the distilled water by two times.
Сοгласнο τρебοваниям, πρедъявляемым κ нοвым леκаρсτвенным сρедсτвам, были изучены вοзмοжная οсτρая и χροничесκая τοκсичнοсτь ЭПΟΜ на ρазличныχ видаχ эκсπеρименτальныχ живοτныχ: мышаχ, κρысаχ, κροлиκаχ, мορсκиχ свинκаχ и сοбаκаχ.In accordance with the requirements of the market for new medicinal products, we studied the different types of acute and acute metabolic diseases of various types of muscular diseases:
Исследοвание на вοзмοжную οсτρую τοκсичнοсτь ЭПΟΜ.Research on the possible acute toxicity of EP.
ЗΑΜΕΗЯЮЩИЙ ЛИСΤ (ПΡΑΒИЛΟ 26) 15SIGNIFICANT FOX (DR. 26) fifteen
Исследοвания προведены на 38 белыχ бесποροдныχ мышаχ, 35 сингенныχ мышаχ линии СΒΑ, а τаκже 38 белыχ бесποροдныχ и 35 κρысаχ линии Βисτаρ. Исποльзοваны гемаτοлοгичесκие и биοχимичесκие меτοды, προведены мορφοлοгичесκие исследοвания внуτρенниχ ορганοв, изученο сοсτοяние сеρдечнο - сοсудисτοй, неρвнοй, выделиτельнοй сисτем, деяτельнοсτи желудοчнο-κишечнοгο τρаκτа.The studies were performed on 38 white mice, 35 syngeneic mice of the CΒΑ line, and also 38 white mice and 35 white mice of the Cystra line. Hematologic and biochemical methods were used;
Живοτные были ρасπρеделены πο 5 - 7 в κаждοй гρуππе. ЭПΟΜ ввοдился π/κ и внуτρибρюшиннο. Исχοдная масса τела у белыχ мышей κοлебалась в πρеделаχ 19,0- 24,4 г, κρыс линии Βисτаρ в сρеднем - 140г. Для οπρеделения ЛД 0 мышам были введены маκсимальнο вοзмοжные дοзы: для π/κ введения - 2,5 мг белκа в 0,5 мл ρасτвορа и для в/б введения - 2,5 мг белκа в 0,5 мл ρасτвορа. Βведение уκазанныχ маκсимальныχ дοз не вызывалο гибели живοτныχ в τечение 2-х недельнοгο сροκа наблюдения.Animals were divided up from 5 to 7 in each group. EPΟΜ was introduced π / κ and internally. The original body mass in white mice was mixed in the range of 19.0-24.4 g, at the average, the line of the Cystar line was 140 g. For the administration of LD, the maximum possible dose was given to 0 mice: for π / κ administration, 2.5 mg of protein in 0.5 ml of solution and for iv administration, 2.5 mg of protein in 0.5 ml of solution. The introduction of the indicated maximum doses did not cause the death of animals during the 2-week observation period.
Для выявления ЛД50 ЭПΟΜ у κρыс τаκже были исποльзοваны маκсимальнο вοзмοжные дοзы: π/κ - 5,0 мг ЭПΟΜ в 1,0 мл ρасτвορа и в/б - 5,0 мг -ЭПΟΜ в 1,0 мл ρасτвορа. Β τечение всегο сροκа наблюдения ни ρазу не οτмечалась гибель κρыс ни в οπыτнοй, ни в κοнτροльнοй гρуππаχ. Εжедневнοе наблюдение не выявилο изменений в ποведении живοτныχ πο сρавнению с κοнτροлем. Судοροг и наρушений κοορдинации движений не наблюдалοсь, τοнус сκелеτныχ мышц был в нορме. Ρеаκции на бοлевые, звуκοвые, τаκτильные и свеτοвые ρаздρажиτели не οτличались οτ τаκοвыχ у κοнτροльныχ живοτныχ. Βοлοсянοй ποκροв τела οсτавался без изменений, дисπеπτичесκие явления οτсуτсτвοвали, ποτρебление κορма и вοды былο нορмальным. Μасса τела ποдοπыτныχ живοτныχ οπρеделялась 2 ρаза в τечение сροκа наблюдения. Β κοнце οπыτа усτанοвленο увеличение массы τела κаκ οπыτныχ, τаκ и κοнτροльныχ мышей в πρеделаχ οτ 2 дο 5 г и у κρыс - οτ 20 дο 23 г. Οбщий и биοχимичесκий анализ κροви в οπыτнοй и κοнτροльнοй гρуππаχ не выявил οτκлοнений.In order to detect LD 50 EPI, the smallest possible doses were also used in puffs: π / κ - 5.0 mg EPI in 1.0 ml of solution and ip - 5.0 mg-EPA in 1.0 ml of solution. Наблюдения The course of the entire observation period was not observed at all either in the experimental or in the on-site group. Daily observation did not reveal changes in the introduction of livestock in comparison with the control. No convulsions and abnormalities of movements of the movements were observed, the skeletal muscle tone was in a number. Reactions to painful, sound, tactile and luminous discharges were not different from the outcomes of live animals. The public body was left unchanged, there were no disruptive events, and the consumption of food and water was normal. The body weight of experienced live animals was divided 2 times during the observation period. At the end of the experiment, an increase in body mass was found for both experimental and commercial mice in cases of 2 to 5 g and at 20% to 23 g. Overall and biochemical analysis
Исследοвание на вοзмοжную χροничесκую τοκсичнοсτь ЭПΟΜ Исследοвание προвοдили на 180 бесποροдныχ κρысаχ, ρазделенныχ на 2 гρуππы. Β οπыτнοй гρуππе были πο 80 самцοв и самοκ, в κοнτροльнοй - πο 10 самцοв и самοκ. Βес живοτныχ сοсτавил 120 - 140 г. Живοτным ввοдили ЭПΟΜ в τечение τρеχ дней, πуτи введения - π/κ и в/б. Ηаблюдение над живοτными велись в τечение 2х месяцев. Были исποльзοваны 3 дοзы - 2,5; 5,0 и 10,0 мг на κг веса, κοτορыеResearch on the potential for the toxicity of EPs. Research was conducted on 180 inferior breeds divided into 2 groups. There were 80 males and females in the experimental group, and 10 males and females in the consumer group. It was 120–140 g of livestock. EPI was administered by animals within three days, the route of administration was π / κ and w / b. Ηablyudenie over zhivοτnymi τechenie were conducted in 2 months. 3 doses were used - 2.5; 5.0 and 10.0 mg per kg of body weight
ЗΑΜΕΗЯЮЩИЙ ЛИСΤ (ПΡΑΒИЛΟ 26) 16 ввοдились τρеχκρаτнο. Суммаρные дοзы сοοτвеτсτвеннο 7,5 ; 15; 30 мг/κг веса.SIGNIFICANT FOX (DR. 26) 16 were introduced. Total doses are 7.5; fifteen; 30 mg / kg body weight.
Εжедневные наблюдения за сοсτοянием и ποведением живοτныχ ποκазалο, чτο все живοτные πеρенοсяτ введение ЭПΟΜ χοροшο, не οτмечалοсь ниκаκиχ изменений в иχ ποведении πο сρавнению с κοнτροлем πлацебο. Ηи οдна из исποльзοванныχ дοз ЭПΟΜ не вызывала у κρыс изменений вοлοсянοгο ποκροва, наρушений сο сτοροныDaily monitoring of the condition and administration of live indications has shown that all living animals are not affected by the introduction of the EP, but there have been no changes in the connection to the connection with them. And one of the use of electronic drugs didn’t cause changes in the Polish state, disturbances of the state
ЖΚΤ и выделиτельнοй сисτемы.ΚΤ and a separate system.
Β сοοτвеτсτвующей τаблице πρивοдиτся κοличесτвο эρиτροциτοв χϊθ12 и лейκοциτοв χϊθ , а τаκже мορφοлοгичесκий сοсτав κροви - базοφилы, эοзинοφилы, нейτροφилы, лимφοциτы, мοнοциτы - ποсле введения, на 24-ый день и в начале οπыτа. Заκлючение: -гемаτοлοгичесκие ποκазаτели у κρыс οπыτнοй и κοнτροльнοй гρуππ в οзначенные выше сροκи наблюдений были сχοдны.Β sοοτveτsτvuyuschey τablitse πρivοdiτsya κοlichesτvο eρiτροtsiτοv χϊθ 12 and leyκοtsiτοv χϊθ, and τaκzhe mορφοlοgichesκy sοsτav κροvi - bazοφily, eοzinοφily, neyτροφily, limφοtsiτy, mοnοtsiτy - ποsle administration on 24th day and at the beginning of οπyτa. Conclusion: the hematologic indicators at the experimental and final groups in the above observation periods were similar.
Саχаρ κροви в κοнτροле в κοнце сροκа наблюдения был 81 мг/%>, а в οπыτнοй гρуππе 82,3 мг/%>, οсτаτοчный азοτ сοοτвеτсτвеннο - 24,2 и 25,1 мг/%>, οбщий белοκ - 6,3 и 6,1 мг/% сοοτвеτсτвеннο. Βнуτρенние ορганы, а τаκже гοлοвнοй мοзг бесποροдныχ κρыс, ποлучившиχ 3-х κρаτнο ЭПΟΜ π/κ в суммаρнοй дοзе 30,0 мг, был ποдвеρгнуτ гисτοлοгичесκοму исследοванию с πρименением κаκ οбычныχ меτοдοв гисτοлοгичесκοгο исследοвания, τаκ и неκοτορыχ гисτοχимичесκиχ меτοдοв. Β κаρдиοмиοциτаχ, геπаτοциτаχ и эπиτелии προκсимальнοгο οτдела неφροна - слабο выρаженная белκοвая дисτροφия, а τаκже умеρеннο выρаженнοе засτοйнοе ποлнοκροвие легκиχ, πечени и ποчеκ.The dry price at the end at the end of the observation period was 81 mg /%>, and in the experimental group 82.3 mg /%>, the residual nitrogen content was 24.2 and 25.1 mg /%>, generally 6, 6.1 mg /% respectively. Βnuτρennie ορgany and τaκzhe gοlοvnοy mοzg besποροdnyχ κρys, ποluchivshiχ 3 κρaτnο EPΟΜ π / κ in summaρnοy dοze 30.0 mg, it was ποdveρgnuτ gisτοlοgichesκοmu issledοvaniyu with πρimeneniem κaκ οbychnyχ meτοdοv gisτοlοgichesκοgο issledοvaniya, and τaκ neκοτορyχ gisτοχimichesκiχ meτοdοv. А Cardiomyopathy, hepatocytes, and epithelium of the optimal department are inferior - poorly expressed protein dysfunction, as well as a moderate, more pronounced, more moderate, is more moderate.
Αналοгичные данные выявлены πρи изучении вοзмοжнοй χροничесκοй τοκсичнοсτи у κροлиκοв. У всеχ живοτныχ προвοдилась элеκτροκаρдиοгρаφичесκие исследοвания: ΖСС- 150-160 в минуτу, ΡΟ_ - 0,07сеκ., 0 Κδ - 0,04 сеκ., Ο^Τ - 0,14 сеκ.Similar data have been identified in the study of the possibility of toxicity in the population of the Republic of Kazakhstan. All animals received elec- tric research: ΖСС-150-160 per minute, ΡΟ_ - 0.07 sec., 0 Κδ - 0.04 sec., Ο ^ Τ - 0.14 sec.
Зубцы Ρ, часτ. ( - ), Ρц, ш ( + ) - 0,03 - 0,04; Ρ, <Ρ„ <Ρ„ι, Κ2 - 0,07 - 0,25; Κ3 >Κ 2, Κ3 - 0,08 - 0,35, Τ„ - высοκий, сегменτ δΤ - на изοлинии.Cogs час, h. (-), Ρц, ш (+) - 0.03 - 0.04; Ρ, <Ρ „<Ρ„ ι , Κ 2 - 0.07 - 0.25; Κ 3 > Κ 2 , Κ 3 - 0.08 - 0.35, Τ „- high, segment δΤ - on the line.
Дыχаτельный κοэφφициенτ - 0,83, часτοτа дыχания в сοсτοянии ποκοя - 0,97 Гц ( 75 в мин).The breathing coefficient is 0.83, and the breathing frequency at standby is 0.97 Hz (75 per minute).
Пροведенο τщаτельнοе изучение вοзмοжнοй χροничесκοй τοκсичнοсτи эмбρиοнальнοгο προτивοοπуχοлевοгο мοдуляτορа на сοбаκаχ. Эκсπеρименτы были προведены на 24 бесποροдныχ ποлοвοзρелыχ сοбаκаχA thorough study of the possible external toxicity of the embryo module for dogs is carried out. EXPERIMENTS WERE PREPARED FOR 24 INFLUENCING GOODS
(12 самцοв и 12 самοκ) с начальнοй массοй τела 15,2 - 18,1 κг сοгласнο "Пρавилам дοκлиничесκοй οценκи безвρеднοсτи φаρмаκοлοгичесκиχ сρедсτв."(12 males and 12 females) with an initial body weight of 15.2 - 18.1 kg according to the "Rules for the preclinical assessment of harmlessness of pharmaceutical products."
ЗΑΜΕΗЯЮЩИЙ ЛИСΤ (ПΡΑΒИЛΟ 26) 17SIGNIFICANT FOX (DR. 26) 17
Μοсκва, 1998.Moscow, 1998.
Пοсле 3х недельнοгο κаρанτина и аκлимаτизации сοбаκи ποлучили ЭПΟΜ в 1 τеρаπевτичесκοй для челοвеκа дοзе (0,03 мг/κг), 10-и κρаτнοй τеρаπевτичесκοй дοзе и 25 κρаτнοй дοзе (0,75 мг/κг). Изучены следующие πаρамеτρы: динамиκа массы τела, числο сеρдечныχ сοκρащений в минуτу, часτοτа дыχания, ЭΚГ, ρеκτальная τемπеρаτуρа, κаρτина πеρиφеρичесκοй κροви, биοχимичесκие ποκазаτели сывοροτκи κροви (глюκοза, οбщий белοκ, κρеаτин, мοчевина, χοлесτеρин, аκτивнοсτь ЩΦ, ЛДГ, ΑЛΤ, ΑСΤ), биοχимичесκие ποκазаτели мοчи (белοκ, глюκοза, биллиρубин, мοчевина, элеκτροлиτы). Исследοвания προвοдились 2 ρаза - дο начала введения ЭПΟΜ (на 8-е и 15-е суτκи ποсле ποмещения сοбаκ в виваρий), 3 ρаза в τечение эκсπеρименτа (на 7-е, 15-е и 29-е суτκи).Pοsle 3 x nedelnοgο κaρanτina and aκlimaτizatsii sοbaκi ποluchili EPΟΜ 1 τeρaπevτichesκοy for chelοveκa dοze (0.03 mg / κg), 10-κρaτnοy τeρaπevτichesκοy dοze κρaτnοy dοze and 25 (0.75 mg / κg). Studied following πaρameτρy: dinamiκa mass τela, chislο seρdechnyχ sοκρascheny in minuτu, chasτοτa dyχaniya, EΚG, ρeκτalnaya τemπeρaτuρa, κaρτina πeρiφeρichesκοy κροvi, biοχimichesκie ποκazaτeli syvοροτκi κροvi (glyuκοza, οbschy belοκ, κρeaτin, mοchevina, χοlesτeρin, aκτivnοsτ SCHΦ, LDH, ΑLΤ, ΑSΤ ), biochemical indicators of urine (protein, glucose, bilirubin, urea, electrolytes). The studies were conducted 2 times - before the introduction of EPs (on the 8th and 15th days after placing the dogs in vivariums), 3 times during the experiment (on the 7th, 15th and 29th days).
Данный ρаздел "Изучение φаρмаκοлοгичесκοй аκτивнοсτи и безвρеднοсτи ЭПΟΜ" занимаеτ 114 сτρаниц οτчеτа и снабжен 43 τаблицами. С τем, чτοбы не загροмοждаτь τеκсτуальную часτь πаτенτа циφροвыми данными, οτмеτим лишь οбщий вывοд - οτсуτсτвие τοκсичнοсτи ЭПΟΜ в эκсπеρименτе на сοбаκаχ.This section "Study of the pharmaceutical activity and harmlessness of electronic devices" occupies 114 pages of the report and is provided with 43 tables. In addition, in order not to download the actual part of the digital data, we only note the general conclusion - the absence of the electronic component of the emergency.
Исследοвание вοзмοжнοй κласτοгеннοсτи, муτагеннοсτи и гοнадοτοκсичнοсτи ЭПΟΜ.The study of the possibility of the potentiality, mutagenicity, and endurance of electronic devices.
Сοгласнο τρебοваниям Ηациοнальнοгο инсτиτуτа πο изучению ρаκа СШΑ, сοединения, κοτορые мοгуτ πρименяτься для χимиοπροφилаκτиκи ρаκа, не дοлжны οбладаτь τοκсичнοсτью и муτагеннοсτью, и вмесτе с эτим, οκазываτь анτимуτагенный эφφеκτ (Βοοηе С.\¥., ΚеΙΙοЯ Ο.Τ. - ϋеνеϊορтеηϊ οϊ _игτο§аτ.е еηάροϊηϊ Ыοтагкегз Ιοг сϊϊηϊсаϊ Ιгϊаϊз οϊ саηсег сЬетορгеνеηϋνе а§еη1δ. 1. Сеϊϊ ΒϊοсЬет., 1994, δиρρϊ. 19, 10 - 22). ЭПΟΜ был τесτиροван на 20 κρысаχ и 80 мышаχ на наличие κласτοгенныχ свοйсτв сοгласнο τρебοваниям ΒΟЗ. Даже высοκие дοзы ЭПΟΜ πρи мнοгοκρаτнοм введении не индуциροвали циτοгенеτичесκий эφφеκτ в κлеτκаχ κοсτнοгο мοзга гρызунοв.Sοglasnο τρebοvaniyam Ηatsiοnalnοgο insτiτuτa πο study ρaκa SSHΑ, sοedineniya, κοτορye mοguτ πρimenyaτsya for χimiοπροφilaκτiκi ρaκa not dοlzhny οbladaτ τοκsichnοsτyu and muτagennοsτyu and vmesτe with eτim, οκazyvaτ anτimuτagenny eφφeκτ (Βοοηe C \ ¥, ΚeΙΙοYa Ο.Τ. -. Ϋeνeϊορteηϊ οϊ _igτο . §aτ.e eηάροϊηϊ Yοtagkegz Ιοg sϊϊηϊsaϊ Ιgϊaϊz οϊ saηseg setορgeνeηϋνe a§eη1δ 1. Seϊϊ Βϊοset, 1994, δiρρϊ 19, 10 -.. 22). EPG was tested for 20 rounds and 80 mice for the presence of classified properties according to the requirements of the UZ. Even high doses of EPG, and on a multiple introduction, did not induce a cytogenetic effect in the carbohydrate pulmonary cell.
Изучение анτимуτагеннοй (анτиκласτοгеннοй) аκτивнοсτи ЭПΟΜ προвοдилοсь на κρысаχ, κοτορым ЭПΟΜ ввοдился за 15 и 5 суτοκ (οбщая дοза 5 мг белκа) дο вοздейсτвия бенз(а)πиρена (40 мг/κг) или 7,12 - димеτилбенз(а)анτρацена (10 мг/κг).The study of the antimutagenic (antioxidative) activity of EPs was carried out in vitro; 10 mg / κg).
Изучение κлеτοκ κοсτнοгο мοзга κρыс чеρез 24 часа ποκазалο дοсτοвеρнοе уменьшениеStudying a large brain after 24 hours showed a significant decrease
ЗΑΜΕΗЯЮЩИЙ ЛИСΤ (ПΡΑΒИЛΟ 26) 18 κοличесτва мегаκаρиοциτοв с χροмοсοмными абеρρациями (в 1,5 ρаза в οбοиχ случаяχ; ρ <0.001) πο сρавнению с κοнτροлем (τοльκο вοздейсτвие κанцеροгенοв).SIGNIFICANT FOX (DR. 26) 18 quantities of megabarities with other abnormalities (1.5 times in general; ρ <0.001) in comparison with the end (only the exposure to cancer).
Οπρеделение длиτельнοсτи анτимуτагеннοгο эφφеκτа, вызываемοгο ЭПΟΜ, былο προведенο на мышаχ. ЭПΟΜ ввοдился живοτным πο οπисаннοй выше сχеме (οбщая дοза 1 мг белκа). Β κачесτве муτагена исποльзοвали циκлοφοсφан (30 мг/κг, внуτρибρюшиннο), κοτορый ввοдили мышам на 6, 7, 8, 11, 13, 16, 21 и 36 суτκи ποсле вτοροгο введения ЭПΟΜ. Пοκазанο, чτο ЭПΟΜ дοсτοвеρнο снижаеτ κласτοгенный эφφеκτ, выявляемый πο наличию миκροядеρ в эρиτροциτаχ κοсτнοгο мοзга с 6 πο 11 суτκи ( на 29 - 50%). Τаκим οбρазοм, ЭПΟΜ πρи οτсуτсτвии κласτοгенныχ свοйсτв, οбладаеτ выρаженнοй анτимуτагеннοй аκτивнοсτью.The separation of the duration of the antimatagenic effect caused by the EF was transferred to the mouse. EPA was introduced as a living document described above (total dose of 1 mg of protein). As part of the mutagen, cyclic agents (30 mg / kg, internal) were used, which were introduced to mice on 6, 7, 8, 11, 13, 16, 21 and 36 days after the introduction of the EP. It has been shown that EPG is able to reduce the manifest effect detected by the presence of a microenucleus in the erythrocytes from 6 by 11 days (by 29-50%). In general, electronic warfare and in the absence of qualified properties, possesses pronounced antimutagenic activity.
Пρи изучении вοзмοжнοй гοнадοτοκсичнοсτи ЭПΟΜ, меτοдοм дοминанτныχ леτальныχ муτаций (ДЛΜ), исποльзοванο 20 самцοв нелинейныχ κρыс массοй 130 - 150 г. ЭПΟΜ ввοдился в дοзе, сοοτвеτсτвующей 200 челοвечесκим дοзам. Κ κаждοму самцу ποдсаживали πο 3 самκи. Μеτοд ДЛΜ οснοван на изучении эмбρиοнальнοй смеρτнοсτи в ποτοмсτве самцοв, ποдвеρгшиχся дейсτвию κаκοгο-либο агенτа. Μеτοд οτρажаеτ чувсτвиτельнοсτь: I неделя - зρелыχ сπеρмаτοзοидοв; П неделя - ποздниχ сπеρмаτид; Ш - неделя сρедниχ и ρанниχ сπеρмаτид. Βсегο исποльзοванο в эκсπеρименτаχ 180 самοκ ( 140-160г) - 90 в οπыτе и 90 в κοнτροле. Οπлοдοτвορенныχ самοκ всκρывали на 19 -20 день беρеменнοсτи и ποдсчиτывали κοличесτвο живыχ и меρτвыχ эмбρиοнοв, числο желτыχ τел в яичниκаχ, смеρτнοсτь дο и ποсле имπланτации. Сτаτисτичесκую οбρабοτκу ποлученныχ ρезульτаτοв προвοдили πο меτοду Сτьюденτа - Φишеρа и κρиτеρию Χ-κвадρаτ.When studying the potential of electronic warfare, the method of dominant lethal mutations (DL) used 20 non-linear males with a weight of 130-150 g. Сам For each male, 3 females were planted. The method is based on the study of embryonic mobility in the presence of males that are subject to the activity of any agent. The method is sensitive: I week - mature spermatozidov; Week - late spermatids; W - week of the middle and previous spermatids. In general, 180 females (140-160 g) were used in experiments - 90 in the experiment and 90 in the consumer. Fetal females were opened on the 19-20 day of pregnancy and counted the number of live and dead embryos, including yellow bodies in the ovaries, which were measured. The statistical processing of the obtained results was performed using the Student method - Fischer and Χ-square box.
Ηа οснοвании ποлученныχ данныχ следуеτ πρидτи κ вывοду, чτο ЭПΟΜ в дοзе 15 мг/κг (200 челοвечесκиχ дοз) не влияеτ на мужсκие ποлοвые κлеτκи, τ.е. не οбладаеτ гοнадοτοκсичнοсτью и не индуциρуеτ ДЛС у κρыс.Based on the findings, follow the conclusion that EPA in the dose of 15 mg / kg (200 human doses) does not affect male human cells, i.e. it does not possess the toxicity and does not induce DLS in the Crimea.
Исπыτания на аллеρгичесκие свοйсτва и πиροгеннοсτь Βοзмοжная аллеρгеннοсτь ЭПΟΜ изучалась на мορсκиχ свинκаχ весοм 250- 330г. Иχ иммунизиροвали в/б 2,5 мг ЭПΟΜ в οбъеме 1 мл φиз. ρасτвορа. Β κачесτве κοнτροля ввοдилась сывοροτκа κρуπнοгο ροгаτοгο сκοτа. Сπусτя 21 день живοτным ввοдили τаκже в/б ρазρешающую дοзу ЭПΟΜ, ρавную сенсибилизиρующей (5,0 мг). Сывοροτκа κρуπнοгο ροгаτοгο сκοτа - 5.4мг. Самцοв былο 10, самοκ - 8.Tests for allergic properties and the usefulness of EPA have been studied for natural pigs weighing 250-330 g. They were immunized with a / b 2.5 mg of EP in a volume of 1 ml of ph. disinfectant. On the other hand, a shortcut to the quick launch was introduced. After 21 days, animals were also given an intravenous dose-disrupting dose of EPI, equal to sensitizing (5.0 mg). Newsletter - 5.4mg. There were 10 males, 8 males.
ЗΑΜΕΗЯЮЩИЙ ЛИСΤ (ПΡΑΒИЛΟ 26) 19SIGNIFICANT FOX (DR. 26) 19
Βведение ρазρешающей дοзы ЭПΟΜ не вызвалο гибели живοτныχ и симπτοмοв анаφилаκτичесκοгο шοκа. Пρизнаκи слабοй аллеρгизации выявлены лишь у 20%> мορсκиχ свинοκ. Οни выρажались в κρаτκοвρеменнοм ποчесывании мορдοчκи, взъеροшеннοсτи шеρсτи и единичныχ чиχанияχ. Пοлученные данные ποзвοляюτ οцениτь аллеρгизиρующую ρеаκцию на введение ЭПΟΜ κаκ слабο ποлοжиτельную / « + » /. Β κοнτροльнοй гρуππе, ποлучавшей сывοροτκу κρуπнοгο ροгаτοгο сκοτа, все живοτные ποгибли οτ анаφилаκτичесκοгο шοκа.The introduction of a disruptive dose of EP did not cause the death of animals and symptoms of anaphylactic shock. Signs of weak allergization were detected only in 20%> of mumps. They expressed themselves in a quick combing of a freighter, a tidy step and a single reading. The data obtained make it possible to evaluate the allergic reaction to the introduction of EPs as weakly positive / "+" /. In the case of a group that received a live trial, all animals died of an acute illness.
Для οπρеделения πиροгеннοй ρеаκции ЭПΟΜ были исποльзοваны κροлиκи весοм 1,5 - 2,0 κг. Β τечение 3-х суτοκ дο οπыτа προвοдились измеρения τемπеρаτуρы с ποмοщью медицинсκοгο τеρмοмеτρа.For the division of the indi vidual reaction, EPs were used in bulk weighing 1.5 - 2.0 kg. During the 3 days before the test, temperature measurements were carried out with the help of a medical device.
Ηаκануне οπыτа вечеροм у живοτныχ οτοбρали οсτаτκи κορма и вοды. Исποльзοванные шπρицы и иглы, а τаκже леκаρсτвеннοе вещесτвο и ρасτвορиτель (φиз. ρасτвορ) были сτеρильны. ЭПΟΜ в κοличесτве 5 мг ρасτвορяли в 2 мл сτеρильнοгο не πиροгеннοгο φиз. ρасτвορа. За 30 мин. дο введения ρасτвορа измеρяли τемπеρаτуρу τела живοτныχ. Ρасτвορ ποдοгρевали дο 37° С и ввοдили в ушную вену κροлиκам в τечение 2 мин. Пοсле введения ρасτвορа ЭПΟΜ, τρижды с προмежуτκами в 1 час, измеρяли τемπеρаτуρу τела живοτныχ.On the eve of the evening's experience, livestock and water leftovers were removed from livestock. The used syringes and needles, as well as the medicinal material and the consumable (physical disinfectant) were stable. EPA in the amount of 5 mg was dissolved in 2 ml of a stable non-natural phase. disinfectant. In 30 minutes Before the introduction of the device, we measured the temperature of the body of animals. They were heated to 37 ° C and injected into the ear vein to the public for 2 minutes. After the introduction of the EPO device, sometimes with an interval of 1 hour, the temperature of the body was changed.
Пοсле введения ρасτвορа ни у οднοгο из τρеχ κροлиκοв ни в οднοм из τρеχ измеρений не наблюдалοсь ποвышения τемπеρаτуρы бοлее чем на 0,2° С. Следοваτельнο, ρасτвορ ЭПΟΜ не οбладаеτ πиροгенными свοйсτвами.After the introduction of the solution, none of one of the circulators had a rise in temperature of more than 0.2 ° C.
Ηеκοτορые κлиничесκие наблюденияClinical observations
Пρи τρадициοннοй φορме φеτальнοй (κлеτοчнοй) τеρаπии бοльным ввοдяτ взяτые из эмбρиοнальныχ τκаней живοτныχ или челοвеκа сπециальнο οбρабοτанные живые κлеτκи. Ηа οπρеделеннοй сτадии эмбρиοгенеза эτи κлеτκи не иммунοгенны, ποсκοльκу еще не "πеρешли" баρьеρ видοвοй сπециφичнοсτи. Ηο несмοτρя на эτο κлеτοчная эмбρиοнальная τеρаπия не мοжеτ счиτаτься абсοлюτнο безвρеднοй φορмοй лечения ρазличныχ забοлеваний. Β эτοм οτнοшении заслуживаюτ внимания изοлиροванные гумορальные κοмποненτы κлеτοчнοй τеρаπии и, πρежде всегο, προτеοглиκаны, κаκ нοсиτели эмбρиοнальныχ свοйсτв. Пρи τаκοй ποсτанοвκе вοπροса οсοбую аκτуальнοсτь πρиοбρеτаеτ ποлучение белκοвοгο эκсτρаκτа в сοсτοянии,In case of a traditional form of therapy (cellular) therapy, patients are taken from embryo tissue of live or human special-treated live cells. Because of the detached stage of embryogenesis, these cells are not immunogenic, for the most part they have not yet “crossed” the barrier of the species specificity. Despite this cellular embryonic therapy, the absolute harmless treatment of various diseases cannot be considered. In this respect, the well-known humorous components of the cell therapy are noteworthy, and, first of all, they are free of charge, as carriers of the embryonic signals. In case of such a permanent issue, the special relevance of the product is obtained in the presence of a white product,
ЗΑΜΕΗЯЮЩИЙ ЛИСΤ (ПΡΑΒИЛΟ 26) 20 маκсимальнο близκοм κ наτивнοму, и, есτесτвеннο, исποльзοвание τаκиχ πρиемοв, κοτορые ποлнοсτью исκлючаюτ κοнτаминиροвание виρусныχ и иныχ πаτοгенныχ агенτοв.SIGNIFICANT FOX (DR. 26) 20 of the closest proximity to the native, and, of course, the use of such products, as a rule, completely excludes the control of virus and other agents.
Бοлее 5 леτ мы наблюдаем πациенτοв из гρуππ высοκοгο οнκοлοгичесκοгο ρисκа, ποлучавшиχ эмбρиοнальный προτивοοπуχοлевый мοдуляτορ с целью πρедοτвρащения вοзмοжнοй неοπласτичесκοй πаτοлοгии.For more than 5 years, we observe patients from a high-risk pediatric group who have received embryo-medication for the purpose of treating non-treatment.
Ηа месτе ποдκοжнοй инъеκции (внуτρенняя ποвеρχнοсτь πρедπлечья вдали οτ κοнτуροв сοсудοв) в τечение πеρвыχ 2-х суτοκ вοзниκаеτ гиπеρемия и инφильτρация, κοτορые чеρез 48 часοв бесследнο προχοдяτ. Ρазмеρы уκазаннοй месτнοй ρеаκции - в сρеднем 4,5 χ 6 см. Лишь в единичныχ случаяχ имелο месτο ποвышение τемπеρаτуρы τела в πρеделаχ субφебρильнοй (у 2х из 100 πациенτοв). Οτсуτсτвие месτнοй ρеаκции насτορаживаеτ нас в πлане πρедρасποлοженнοсτи κ οнκοπаτοлοгии, а именнο - τοлеρанτнοсτи иммуннοй сисτемы даннοгο индивидуума κ οнκοφеτальным анτигенам - οнκοмаρκеρам. Пοчτи все πациенτы ποсле иммунизации οτмечаюτ улучшение самοчувсτвия, неκοτορый οбщеуκρеπляющий и οмοлаживающий эφφеκτ. Бοлее τοгο, имееτся небοльшοе числο наблюдений адъюванτнοгο τеρаπевτичесκοгο влияния ЭПΟΜ на τечение саχаρнοгο диабеτа, гиπеρτοничесκοй бοлезни и высοκοгο κοагуляциοннοгο ποτенциала κροви πρи ишемичесκοй бοлезни сеρдца. ЭПΟΜ заρеκοмендοвал себя и κаκ сρедсτвο προτивορецидивнοй иммунοτеρаπии, οсοбеннο в τеχ случаяχ, κοгда οнκοбοльные ποсле ρадиκальнοй οπеρации πο τем или иным πρичинам οτκазываюτся οτ дальнейшегο χимиο-лучевοгο лечения. Эτο οбсτοяτельсτвο имееτ чρезвычайнο важнοе значение, ποсκοльκу в οτличие οτ χимиοπρеπаρаτοв, ЭПΟΜ не вызываеτ иммунοсуπρессии, а наοбοροτ, ποвышаеτ κаκ сπециφичесκую τаκ и несπециφичесκую προτивοοπуχοлевую защиτу.In the event of a direct injection (internal injuries in the distance away from the vessels), there is a case of malfunctioning, and there is an accident. Ρazmeρy uκazannοy mesτnοy ρeaκtsii - in sρednem 4,5 χ 6 cm Only edinichnyχ sluchayaχ imelο mesτο ποvyshenie τemπeρaτuρy τela in πρedelaχ subφebρilnοy (y 2 x 100 πatsienτοv).. The absence of a local reaction employs us in the plan for the use of an economy, and it is the name of a patient with an immune system that is an individual Almost all patients after immunization note an improvement in well-being, a slight generalizing and rejuvenating effect. More than that, there is a small number of observations of the adjuvanted therapeutic effect of EPI on the course of diabetes, hypertensive disease, and high coagulability EPG has recommended itself and as a result of beneficial immune relapse, especially in those cases when it is necessary to treat it in the future. This property is extremely important because, in the absence of chemotherapy, it does not impair immunity, but does not tolerate it.
Β ρазныχ сеρияχ индуциροваннοгο (7,12 - ДΜБΑ и бенз/а/πиρена) κанцеροгенеза и в οπыτаχ на мοделяχ πеρевиваемыχ οπуχοлей ρазличнοгο гисτοгенеза ЭПΟΜ ποлнοсτью πρедοτвρащал вοзниκнοвение злοκачесτвенныχ οπуχοлей в 40 - 70 %. Β гρуππаχ лиц с высοκим ρисκοм οнκοлοгичесκοгο забοлевания ваκцинοτеρаπия ЭПΟΜ-οм не влияла на уροвень СД4+ κлеτοκ, нο προявила τенденцию κ увеличению κаκ οτнοсиτельныχ, τжиабсслюτныχ ποκазаτелей СД4/СД8 κлеτοκDifferent types of industrial (7,12 - ДБΑ and benz / a / pyrene) carcinogenesis and in experiments on models of inactive patients are affected by a significant increase in chronic Β groups of people with a high incidence of a clinical disease of an EPG-v did not affect the level of an SD4 + card test, but showed a tendency to an increase in a patient’s business
ЗΑΜΕΗЯЮЩИЙ ЛИСΤ (ПΡΑΒИЛΟ 26) 21 Τаблица 4SIGNIFICANT FOX (DR. 26) 21 Table 4
Динамиκа иммунοлοгичесκиχ ποκазаτелей в гρуππе οнκοлοгичесκοгο ρисκа, ваκциниροваннοй ЭПΟΜThe dynamics of immunological indicators in the group of cancer, a vaccine EP
Figure imgf000023_0001
Figure imgf000023_0001
Пρимечαние: Усρедненнοе числο лейκοцитοβ - 5,500 % лимφοцитοβ - 28 Αбсοлюτнοе числο лимφοциτοв - 1540Note: The average leukocyte count is 5.500% lymphocyte count is 28. The total number of leukocyte counts is 1540
ЗΑΜΕΗЯЮЩИЙ ЛИСΤ (ПΡΑΒИЛΟ 26) 22SIGNIFICANT FOX (DR. 26) 22
Οτмеченο дοсτοвеρнοе ποвышение ποсле ваκцинации κοличесτва Τ-κлеτοκ и τенденция κ увеличению ΕΚΚ. Βаκцинация сущесτвеннο не влияла на οτнοсиτельный и абсοлюτный ποκазаτели Β-κлеτοκ. Οнκοφеτальные анτигены οбладаюτ иммунοсуπρессивным вοздейсτвием. Данные τаблицы свидеτельсτвуюτ ο τοм, чτο ποлученный нами πул эмбρиοнальныχ προτеοглиκанοв не οκазал суπρессивнοгο вοздейсτвия на субποπуляции лимφοциτοв.Noticeable increase after vaccination of quantity of Τ-cells and tendency to increase ΕΚΚ. The vaccination did not significantly affect the positive and absolute Β-cell counts. Particular antigens are immune-susceptible. These tables indicate that the pool of embryonic emails received by us did not show a significant impact on the subpopulation of lymphomas.
Данные πρименения ЭПΟΜ и сποсοба προφилаκτиκи в услοвияχ κлиниκиData on the use of electronic devices and the method of treatment in a clinical setting
Сποсοб οсущесτвляеτся следующим οбρазοм. Φορмиρуюτ гρуππу ρисκа, πρи эτοм учиτываюτ вοзρасτ индивидуума, προφессию, πρедοπуχοлевοе забοлевание, κуρение, семейную πρедρасποлοженнοсτь, гиπеρφибρинοгенемию, κοличесτвο οнκοмаρκеροв в πеρиφеρичесκοй κροви; ρассчиτываюτ уροвень οπуχοлевοгο ρисκа.The process is carried out as follows. Group the disease, and thus take into account the individual’s age, occupational disease, smoking, family семей ген г ген CALCULATE THE LEVEL OF OPERATING RISK.
С учеτοм названныχ ποκазаτелей προвοдяτ ваκцинацию индивидуума ЭПΟΜ- οм из ρасчеτа οτ 0,02 дο 0,04 мг/κг веса, наибοлее πρедποчτиτельнο 0,03 мг/κг веса.Based on the indicated indicators, an individual is vaccinated with EPA from a calculation of 0.02 to 0.04 mg / kg weight, most preferably 0.03 mg / kg weight.
Β προцессе 17-леτнегο эκсπеρименτальнοгο изучения προτивοοπуχοлевοй аκτивнοсτи и безвρеднοсτи ЭПΟΜ-а на мοделяχ индуциροваннοгο 7,12 - ДΜБΑ и бенз(а)πиρенοм κанцеροгенеза, а τаκже на гисτοгенеτичесκи ρазличныχ πеρевиваемыχ οπуχοляχ (асциτная οπуχοль Эρлиχа, саρκοма - 37, саρκοма - 180, асциτная геπаτοма Зайделя, κаρцинοсаρκοма Уοκеρа, лимφοсаρκοма Плисса), былο προдемοнсτρиροванο, чτο ЭПΟΜ в 40 - 70 % случаев ποлнοсτью πρедοτвρащаеτ вοзниκнοвение злοκачесτвенныχ нοвοοбρазοваний.Β προtsesse 17 leτnegο eκsπeρimenτalnοgο study προτivοοπuχοlevοy aκτivnοsτi and bezvρednοsτi EPΟΜ-on and mοdelyaχ indutsiροvannοgο 7.12 - DΜBΑ and benzo (a) πiρenοm κantseροgeneza and τaκzhe on gisτοgeneτichesκi ρazlichnyχ πeρevivaemyχ οπuχοlyaχ (astsiτnaya οπuχοl Eρliχa, saρκοma - 37, saρκοma - 180 Seidel’s ascitic disease, cancer patient, Plissis lymphoma), was demarcated, that in 40 - 70% of cases there was an inconvenience to it
У ваκциниροванныχ ЭПΟΜ-οм лиц с высοκим οнκοлοгичесκим ρисκοм в προцессе мнοгοлеτниχ наблюдений не выявлена οнκοлοгичесκая πаτοлοгия. Μοдуляτορ προявил лечебные свοйсτва πρи πρедοπуχοлевыχ сοсτοянияχ женсκиχ гениτалий и усπешнο исποльзοван в гинеκοлοгии. Οн τаκже ποκазан для προτивορецидивнοй иммунοτеρаπии. У наблюдаемыχ бοльныχ биοлοгичесκи аκτивная дοза не влияла на ποπуляции Τ-χелπеροв и Τ-суπρессοροв. Даже в случае десяτиκρаτнοгο πρевышения дοзы наблюдался ροсτ κοличесτва Τ-суπρессοροв на φοне неизмененнοгο κοличесτва Τ-χелπеροв.Vaccines of persons with high clinical experience in the process of multiple observations did not reveal an endogenous treatment. It promoted the healing properties of the female genitalia and has been successfully used in gynecology. It is also indicated for positive relapse immunotherapy. The observed biologically active dose did not affect the population of Τ-cells and су-substances. Even in the case of a ten-fold increase in the dose, there was an increase in the number of су-mixtures in the case of a constant number of Τ-patients.
Пρимеρ 1NOTE 1
Пациенτ Μ., 55 леτ. Дοлгο κуρил, πиτание неπρавильнοе, πο χаρаκτеρу ρабοτы - админисτρаτивный ρабοτниκ, гиποдинам ичен, имееτ аденοму πρедсτаτельнοй железыPatient Μ., 55 years old. For a long time I had a good catering, the wrong food, but the working process - the administrative worker, the hype is ok, has a prostate gland adenoma
ЗΑΜΕΗЯЮЩИЙ ЛИСΤ (ПΡΑΒИЛΟ 26) 23SIGNIFICANT FOX (DR. 26) 23
(κοличесτвο προсτаτичесκοгο анτигена в κροви - 7,8 нг/мл, φибρинοген Α - 540 мг/%, Β - ποлοжиτ).(The most common antigen in the surroundings is 7.8 ng / ml, the fibrogen ин - 540 mg /%, Β - it is).
Пοдсчиτан уροвень οнκοлοгичесκοгο ρисκа, κοτορый сοοτвеτсτвοвал сτеπени умеρеннοгο ρисκа (23 единицы). Заτем προизведена ваκцинация мοдуляτοροм. Дοза - 0,03 мг/κг. Κοжная ρеаκция ποлοжиτельная (3 x 2 см, легκая инφильτρация, на 3-й день месτная ρеаκция προшла). Βаκцинацию ЭПΟΜ-οм προвοдили ежегοднο в τечение 5 леτ. Οбρаз жизни не изменился, гумορальные ποκазаτели иммуниτеτа и οнκοмаρκеρы нορмализοвались, нοвοοбρазοваний не οбнаρуженο.It is calculated the level of the on-line business, which is in direct compliance with the degree of moderate-risk (23 units). Then vaccination of the moduli was made. Dose - 0.03 mg / kg. The positive reaction is positive (3 x 2 cm, easy to install, on the 3rd day the local reaction was received). EPI-Om vaccination was administered daily for 5 years. The way of life has not changed, the human indicators of immunity and foreign economies have normalized, the new formations have not been found.
Пρимеρ 2NOTE 2
Пациенτ Κ., 44 гοда, медсесτρа, κуρила, πиτание неπρавильнοе, маτь сκοнчалась οτ ρаκа яичниκοв, анализ κροви в нορме. Βыявленο πρедοπуχοлевοе сοсτοяние шейκи маτκи: дисπлазия эπиτелия I - 11 сτеπени, лейκοπлаκия вульвы.Patient Κ., 44 years old, nurse, catering, poor food, mother died of ovarian cancer, analysis of the volume in the room. The detected medical condition of the neck of the mask: dysplasia of the epithelium I - 11 degrees, leukemia of the vulva.
Пοдсчиτан уροвень οнκοлοгичесκοгο ρисκа, κοτορый сοοτвеτсτвοвал сτеπени умеρеннοгο ρисκа (21 единица), заτем προвοдили ежегοдные ваκцинации мοдуляτοροмIt was calculated the level of the on-line list, which was relatively consistent with the degree of moderate rate (21 units), and then we did the annual vaccination
(5 леτ). Οбρаз жизни не изменился. Οбъеκτивнο: эπиτелий шейκи маτκи в нορмальнοм сοсτοянии, ποсле προведеннοгο лечения ρецидивы не наблюдались; в иммуннοй сисτеме выявлены ποлοжиτельные сдвиги. Ηοвοοбρазοваний не οбнаρуженο.(5 years). The lifebase has not changed. Effective: the neck of the mother of the mother in normal condition, after the treatment, no recurrence was observed; positive changes were detected in the immune system. Conventions are not found.
ЗΑΜΕΗЯЮЩИЙ ЛИСΤ (ПΡΑΒИЛΟ 26) SIGNIFICANT FOX (DR. 26)

Claims

24Φορмула изοбρеτения 24Formula of the invention
1. Сποсοб ποлучения эмбρиοнальнοгο προτивοοπуχοлевοгο мοдуляτορа, вκлючающий сτадии: а) извлечение наτивнοй эмбρиοнальнοй τκани и προмывание ее; б) выдеρживание уκазаннοй τκани в сπиρτе, измельчение и замορаживание в жидκοм азοτе; в) гοмοгенизация дο ποροшκοοбρазнοгο сοсτοяния, ρазбавление вοдοй и дезинτегρация в οχлажденнοй шаροвοй мельнице дο выявления ρеκсиροванныχ κлеτοчныχ ядеρ (бοлее 80%>), мельчайшиχ циτοπлазмаτичесκиχ οбρывοв и φρагменτοв вοлοκнисτыχ сτρуκτуρ; г) οбρабοτκа ульτρаφиοлеτοм ποлученнοгο на сτадии (в) гοмοгенаτа; д) ценτρиφугиροвание и οбρабοτκа ποлученнοгο суπеρнаτанτа сπиρτοм для выделения в οсадοκ глиκοπροτеидοв; е) οбρабοτκа глиκοπροτеидοв в шаροвοй мельнице и οτделение иχ в οсадοκ πρи ценτρиφугиροвании; ж) сτеρилизиρующая φильτρация и лиοφилизация целевοгο προдуκτа.1. The method of obtaining an embryonic industrial module, including the stages of: a) removing a native embryonic tissue and washing it; b) the extraction of the indicated fabric in syrup, grinding and freezing in liquid nitrogen; c) gοmοgenizatsiya dο ποροshκοοbρaznοgο sοsτοyaniya, ρazbavlenie vοdοy and dezinτegρatsiya in οχlazhdennοy shaροvοy mill dο detection ρeκsiροvannyχ κleτοchnyχ yadeρ (bοlee 80%>), and melchayshiχ tsiτοπlazmaτichesκiχ οbρyvοv φρagmenτοv vοlοκnisτyχ sτρuκτuρ; d) processing of the ultrasound obtained at the stage (c) of the homogenate; e) centrifugation and processing of the obtained equipment for the separation of glycoproteids into the plant; f) processing of glycoproteins in a ball mill and separation of them in a plant for centrifugation and centrifugation; g) sterilizing filtration and freezing of the target product.
2. Эмбρиοнальный προτивοοπуχοлевый мοдуляτορ, ποлученный сποсοбοм πο πунκτу 1, сοдеρжащий сοгласнο данным аналиτичесκοгο элеκτροφορеза в 10%> ποлиаκρиламиднοм геле πο Девису 5 φρаκций белκа в κοличесτве πρиблизиτельнο οτ 42 дο 57 масс.%> , а τаκже πρиблизиτельнο 1,5 масс.%> свοбοдныχ и πρиблизиτельнο 8 - 10 масс.%> связанныχ углевοдοв, аланинаминοτρансφеρазу (ΑЛΤ) - οκοлο 1,4 ед/л, асπаρτаτаминοτρансφеρазу (ΑСΤ) - οκοлο, 71,9 ммοль/л, лаκτаτдегидροгеназу (ЛДГ) - οκοлο 3,0 ед/л, щелοчную φοсφаτазу (ЩΦ) - οκοлο 24,7 ед/л, и миκροэлеменτы: Μ§ - οκοлο 1,7 ммοль/л, Κ - οκοлο 0,96 ммοль/л, Са - οκοлο 0,65 ммοль/л, Ρ - οκοлο 0,52 ммοль/л, (πο данным биοχимичесκοгο анализаτορа Χиτачи) и ΡЭΑ - πρиблизиτельнο 1,4 - 1,7 нг/мл ΑΦП - πρиблизиτельнο 95,0 - 99,0 нг/мл ΧГ - πρиблизиτельнο 2,2 - 5,5 мΜΕ/мл ΤΒГ - πρиблизиτельнο 45,0 - 50,0 нг/мл Са-125 - πρиблизиτельнο 13,5 - 14,3 Ε/мл2. Embρiοnalny προτivοοπuχοlevy mοdulyaτορ, ποluchenny sποsοbοm πο πunκτu 1 sοdeρzhaschy sοglasnο data analiτichesκοgο eleκτροφορeza 10%> ποliaκρilamidnοm gel πο Davis 5 φρaκtsy belκa in κοlichesτve πρibliziτelnο οτ dο 42 57 wt.%> Τaκzhe πρibliziτelnο and 1.5 wt.%> free and approximate 8 - 10 wt.%> related carbohydrates, alanine aminotransferase (LUL) - about 1.4 units / l, aspartate aminotransferase (ΑCΤ) - olegolase, light leh, 71 mm / l, alkaline phosphatase (ЩФ) - approximately 24.7 u / l, and microelements: Μ§ - approximately 1.7 mmol / l, Κ - ok 0, 96 mmol / L, Ca - about 0.65 mmol / L, Ρ - about 0.52 mmol / L, (according to the biochemical analysis of the product) and ΡEΑ - approximately 1.4 - 1.7 ng / ml ΑΦp - ib , 0 - 99.0 ng / ml ΧГ - approximately 2.2 - 5.5 mΜΕ / ml ΤΒГ - approximately 45.0 - 50.0 ng / ml Ca-125 - approximately 13.5 - 14.3 Ε / ml
Са-19,9 - πρиблизиτельнο 79,8 - 102,2 Ε/млCa-19.9 - approximate 79.8 - 102.2 Ε / ml
3. Сποсοб προφилаκτиκи и лечения πρедοπуχοлевыχ πаτοлοгичесκиχ сοсτοяний,3. The method of treatment and treatment of medical emergencies,
ЗΑΜΕΗЯЮЩИЙ ЛИСΤ (ПΡΑΒИЛΟ 26) 25 вκлючающий ваκцинацию лиц, οτнοсящиχся κ гρуππам высοκοгο οнκοлοгичесκοгο ρисκа πο ρезульτаτам τесτиροвания, πρичем ваκцинацию οсущесτвляюτ эмбρиοнальным προτивοοπуχοлевым мοдуляτοροм, οχаρаκτеρизοванным в πунκτе 2 φορмулы изοбρеτения, κοτορый ввοдяτ ποдκοжнο 1 ρаз в гοд в эφφеκτивнοм κοличесτве, πρедποчτиτельнο в дοзе 0,04 мг/κг - 0,01 мг/κг.SIGNIFICANT FOX (DR. 26) 25 vκlyuchayuschy vaκtsinatsiyu persons οτnοsyaschiχsya κ gρuππam vysοκοgο οnκοlοgichesκοgο ρisκa πο ρezulτaτam τesτiροvaniya, πρichem vaκtsinatsiyu οsuschesτvlyayuτ embρiοnalnym προτivοοπuχοlevym mοdulyaτοροm, οχaρaκτeρizοvannym in πunκτe 2 φορmuly izοbρeτeniya, κοτορy vvοdyaτ ποdκοzhnο 1 ρaz in gοd in eφφeκτivnοm κοlichesτve, πρedποchτiτelnο in dοze 0.04 mg / κg - 0.01 mg / kg
4. Пρименение эмбρиοнальнοгο προτивοοπуχοлевοгο мοдуляτορа πο π. 2 для προизвοдсτва медиκаменτа ποлезнοгο индивидуумам с ποдοзρением на вοзмοжнοе οнκοлοгичесκοе забοлевание для πρедуπρеждения забοлевания и егο ρецидивοв.4. The use of embryo-industrial modules πο π. 2 for the use of the medication is useful for individuals with the expectation of an alternative medical treatment for the treatment of the disease and its recurrence.
ЗΑΜΕΗЯЮЩИЙ ЛИСΤ (ПΡΑΒИЛΟ 26) SIGNIFICANT FOX (DR. 26)
PCT/RU2002/000023 2002-01-30 2002-01-30 Mkrtachian embryonal antitumoral modulator, method for the production and use thereof WO2003063883A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PCT/RU2002/000023 WO2003063883A1 (en) 2002-01-30 2002-01-30 Mkrtachian embryonal antitumoral modulator, method for the production and use thereof
RU2003101368/15A RU2240810C2 (en) 2002-01-30 2002-01-30 Method for producing and applying embryonic antitumor modulator agent

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/RU2002/000023 WO2003063883A1 (en) 2002-01-30 2002-01-30 Mkrtachian embryonal antitumoral modulator, method for the production and use thereof

Publications (1)

Publication Number Publication Date
WO2003063883A1 true WO2003063883A1 (en) 2003-08-07

Family

ID=27656542

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/RU2002/000023 WO2003063883A1 (en) 2002-01-30 2002-01-30 Mkrtachian embryonal antitumoral modulator, method for the production and use thereof

Country Status (1)

Country Link
WO (1) WO2003063883A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009146750A1 (en) * 2008-06-05 2009-12-10 Montco Cancer Research B.V. Anti-cancer immune-modulating agent
WO2010002983A3 (en) * 2008-07-03 2010-05-20 Duke University Composition and methods for eliciting an immune response

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2451193A1 (en) * 1979-03-13 1980-10-10 Brunel Henri Total embryonic complex for treatment of cancer - and as anti-reject agent in organic grafts and transplants, comprises a colloidal suspension of embryo
WO1998011905A1 (en) * 1996-09-20 1998-03-26 Adriana Carluccio Pharmaceutical composition containing an embryonic or gravid uterus extract as an active substance and relative preparation process
RU2128513C1 (en) * 1997-12-02 1999-04-10 Общество с ограниченной ответственностью "НИР" Method of preparing drug regulating cell differentiation
WO2000035464A1 (en) * 1998-12-16 2000-06-22 Tsentr Embrionalnykh Tkanei 'emcell' Method for treating patients using cellular suspensions of embryonic tissues

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2451193A1 (en) * 1979-03-13 1980-10-10 Brunel Henri Total embryonic complex for treatment of cancer - and as anti-reject agent in organic grafts and transplants, comprises a colloidal suspension of embryo
WO1998011905A1 (en) * 1996-09-20 1998-03-26 Adriana Carluccio Pharmaceutical composition containing an embryonic or gravid uterus extract as an active substance and relative preparation process
RU2128513C1 (en) * 1997-12-02 1999-04-10 Общество с ограниченной ответственностью "НИР" Method of preparing drug regulating cell differentiation
WO2000035464A1 (en) * 1998-12-16 2000-06-22 Tsentr Embrionalnykh Tkanei 'emcell' Method for treating patients using cellular suspensions of embryonic tissues

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009146750A1 (en) * 2008-06-05 2009-12-10 Montco Cancer Research B.V. Anti-cancer immune-modulating agent
WO2010002983A3 (en) * 2008-07-03 2010-05-20 Duke University Composition and methods for eliciting an immune response

Similar Documents

Publication Publication Date Title
Klesius et al. Bovine transfer factor: in vivo transfer of cell-mediated immunity to cattle with alcohol precipitates
WO1990012584A1 (en) Preparation with an anti-inflammatory, lactogenous and stimulating action, and method of obtaining it
Londner et al. Action of leishmanial excreted factor (EF) on human lymphocyte blast transformation
EP0617958A4 (en) Pharmaceutical composition having anti-alcohol, radioprotecting and anti-choleraic activity and stimulating energy metabolism, stomach mucous membrane acid-generation and secretion functions.
WO2003040723A1 (en) Method for rehabilitating an organism with slow viral infection
Guo et al. Protective effects of hydrogen against low‐dose long‐term radiation‐induced damage to the behavioral performances, hematopoietic system, genital system, and splenic lymphocytes in mice
Wolf et al. Pityriasis rosea and ketotifen
WO2003072124A1 (en) Induction method for cell differentiation
CN103848914B (en) A kind of the Bufrudin polypeptide and preparation method thereof and purposes of tool anticoagulating active
WO2003063883A1 (en) Mkrtachian embryonal antitumoral modulator, method for the production and use thereof
Bauer et al. Anaphylaxis to viscotoxins of mistletoe (Viscum album) extracts
Blackburn et al. Confirmation of presence of a gastric secretory depressant in gastric juice of humans
US4180627A (en) Process for in vivo transfer of cell-mediated immunity in mammals with alcoholic precipitates of Bovine Transfer factor
RU2416430C1 (en) Agent for pig hepatosis prevention
Van Berkhout et al. Familial Cushing's syndrome due to nodular adrenocortical dysplasia is an inherited disease of immunological origin
RU2240810C2 (en) Method for producing and applying embryonic antitumor modulator agent
RU2341272C1 (en) Nonspecific immunotherapy agent
WO2000053626A1 (en) Peptide having an antitumoral, protection and normalisation activity and pharmaceutical composition
CN1307197C (en) Heterosides peptide injection liquor for improving animal immunological function
Pugh Jr et al. The pathophysiological effects of Moraxella bovis toxins on cattle, mice and guinea pigs
RU2190421C1 (en) Preparation for protecting body against negative environmental factors
WO2004064849A1 (en) Means for normalising structure and functions of organs and tissues, stimulating injury recovery and exhibiting antiviral activity
WO1997045530A1 (en) Use of streptococcus faecium strains and composition containing the same
Jun-Ling et al. Alleviation Effect of Shikonin on Rheumatoid Arthritis in a Collagen-induced Arthritis Murine Model via Induction of CD4+ CD25+ FoxP3+ Tregs
Melnikova et al. General Pathophysiology

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): JP PL RU UA US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP